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resumo 
 
 
A proteína precursora de amilóide (PPA) e a proteína Tau estão relacionadas 
com os marcos histológicos da doença de Alzheimer, uma doença 
neurodegenerativa progressiva e complexa. A PPA é uma glicoproteína 
integral transmembranar que tem duas predominantes vias de processamento 
proteolítico, a via não-amiloidogénica e a via amiloidogénica. A proteína Tau 
encontra-se associada aos microtúbulos, sendo a afinidade dessa ligação 
regulada pela fosforilação de resíduos de serina e treonina. A expressão da 
PPA e da proteína Tau também já foi reportada no testículo. No entanto, ainda 
não foram estabelecidas as suas funções e modificações pós-traducionais 
neste tecido. Assim, analisamos a expressão destas duas proteínas e o seu 
padrão de fosforilação durante a espermatogénese usando como modelos 
murganhos e ratos wild-type. Através de imuno-histoquímica revelamos que a 
PPA, a proteína Tau, a proteína serina/treonina fosfatase (PP) 1α e a PP1γ 
são expressas em toda a espermatogénese. Fosforilação da PPA e da 
proteína Tau foi detetada durante a meiose. Em contraste com a localização 
da PPA-total, a PPA fosforilada na treonina 668 está especialmente localizada 
no núcleo dos espermatócitos. Estes resultados sugerem que a fosforilação da 
PPA e da proteína Tau contribui para a espermatogénese, especialmente na 
meiose. No entanto, são necessários estudos futuros para validar os nossos 
resultados e desvendar a função específica da PPA e da proteína Tau durante 
a espermatogénese e na meiose.  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
keywords 
 
amyloid precursor protein, tau protein, phosphorylation, serine/threonine 
protein phosphatase, spermatogenesis. 
 
 
abstract 
 
The Amyloid precursor protein (APP) and Tau protein are related to 
histopathological hallmarks of Alzheimer’s disease, a progressive and complex 
neurodegenerative disease. APP is a type 1 integral transmembrane 
glycoprotein. There are two predominant proteolytic processing pathways of 
APP, the nonamyloidogenic pathway, and the amyloidogenic pathway. Tau is 
one of the microtubule-associated proteins, and its binding affinity for 
microtubules is regulated by phosphorylation of serine and threonine residues. 
APP and Tau protein expression has also been reported in the testis. However, 
their function and posttranslational modifications in the testis have not been 
established. Thus, we analyzed the expression of these two proteins and their 
phosphorylation patterns during spermatogenesis using wild-type mice and rats 
as models. Through immunohistochemistry we revealed that APP, Tau protein, 
Serine/Threonine Protein Phosphatase (PP) 1α and PP1γ are expressed 
throughout spermatogenesis. APP and Tau are phosphorylated during meiosis. 
In contrast to total-APP localization, phosphorylated APP at Thr668 was 
specially localized in spermatocyte nuclei. These results suggest that 
phosphorylation of APP and Tau protein contribute to spermatogenesis, 
especially in meiosis. However, further research is required to validate our 
results and unravel the specific function of APP and Tau protein during 
spermatogenesis and meiosis. 
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 Alzheimer’s Disease 
Over the last decades societies have been growing older, with the most intensive 
growth in the number of individuals above 85 years old. This scenario represents one of 
the biggest challenges for health care and social systems. Gradual improvement of health 
care, arising from advances in science research, and the social support given to senior 
citizens has significantly contributed to this beneficial tendency. Still, ageing populations 
contribute to an increase in the ratio of age-related diseases, and consequently, an increase 
in the burden for the health care system, thus changing the main concerns of science 
research 1. 
Alzheimer’s disease (AD) was first described in 1907 by Dr. Alois Alzheimer, a German 
psychiatrist and neuropathologist, as “an unusual illness of the cerebral cortex” 2. It’s a 
progressive and complex neurodegenerative disease, and is characterized by an 
irreversible memory loss and intellectual function decline, severe enough to interfere with 
daily functions (reviewed in Thies and Bleiler, 2013 3).  
AD is the most common type of dementia, accounted for an estimated 60% to 80% 
of cases. According to Alzheimer’s Association (http://www.alz.org/) the term dementia 
describes “a variety of diseases and conditions that develop when neurons die or no longer 
function normally”, consequently causing “changes in one’s memory, behaviour, and ability 
to think clearly”. Besides AD, other types of dementia include vascular dementia, dementia 
with Lewy bodies, frontotemporal lobar degeneration, mixed dementia, Parkinson’s 
disease, Creutzfeldt-Jakob disease, and normal pressure hydrocephalus. Each type of 
dementia is associated with distinct symptom patterns and brain abnormalities. AD affects 
people in different ways, but the common symptoms are: memory loss that disrupts daily 
life; challenges in planning or solving problems; difficulty completing familiar tasks; 
confusion with time or place; trouble understanding visual images and spatial relationships; 
new problems with words in speaking or writing; misplacing things and losing the ability to 
retrace steps; decreased or poor judgment; withdrawal from work or social activities; 
changes in mood and personality. Later symptoms include impaired judgment, 
disorientation, confusion, behaviour changes, and difficulty speaking, swallowing, and 
walking (reviewed in Thies and Bleiler, 2013 3).  
World Health Organization estimated that 44.4 million people worldwide were living 
with dementia in 2013, and there are 7.7 million new cases of dementia each year 4. In 
2010, Western Europe was the global burden of disease region with the highest number of 
people with dementia (7.0 million), followed by East Asia with 5.5 million, South Asia with 
4.5 million and North America with 4.4 million 5. According to the Alzheimer Association, in 
the United States of America an estimated 5.2 million of people of all ages have AD in 2013 
(reviewed in Thies and Bleiler, 2013 3). Of those with AD, about 4% are less than 65 years 
old, 13% are 65 to 74 years old, 44% are 75 to 84 years old, and 38% are 85 years or older 
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6 (reviewed in Thies and Bleiler, 2013 3). By 2050, the total estimated prevalence expected 
is 13.8 million of people in United States of America 6 (reviewed in Thies and Bleiler, 2013  
3) and 115.4 million of people worldwide 7.  
 
1.1.1. AD Hallmarks 
AD has as microscopic hallmarks brain abnormalities the extracellular senile plaques 
(also known as neuritic plaques) and intracellular neurofibrillary tangles (NFTs), as 
represented in Figure 1 8. These histological features go along with decreases in synaptic 
density, increases in neuronal loss, neuroinflammatory glial activity and 
neurodegeneration 1. For a neuropathological diagnosis of AD, both senile plaques and 
NFTs are mandatory 9, and can only be confirmed post-mortem at the autopsy 10. 
Senile plaques are neurotoxic and consist of a dense amyloid core of β-amyloid 
peptide (Aβ) of 40 and 42 amino acids (a.a.) in length 11. These plaques are surrounded by 
dystrophic neurites and, precipitate and deposit outside and around neurons, 
predominantly those in the limbic system and cortex. This mechanism will finally lead to 
neuronal death, which is proposed to be responsible for phenotypical dementia in affected 
patients 9.  
Tau is a microtubule-associated protein (MAP), and the major constituent of NFTs. 
Tau’s function is regulated by phosphorylation. In AD, Tau protein is abnormally 
hyperphosphorylated, which leads to Tau polymerization, disruption of microtubule (MT) 
dynamics, and impaired axonal transport. That consequently results in the formation of 
intraneuronal NFTs and finally neuronal death 9.  
 
Figure 1: Alzheimer disease histopathological features in the brain. 
A) Plaques with dystrophic neurites surrounding amyloid cores (arrows). B) Neurofibrillary tangle is present 
within one neuron, and several extracellular tangles are also present (arrows) (taken from 12). 
 
Nowadays, the “amyloid hypothesis” is generally supported. According to this 
hypothesis the abnormal production and aggregation of Aβ, principally the more 
fibrillogenic Aβ42 isoform, are the primary pathogenic events in AD, and NFTs are further 
downstream in the neuropathogenesis. This hypothesis is controversial, because senile 
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plaques and NFTs have been found in the brain of non-demented persons as well, although 
in lower abundance. Additionally, the precise sequence and repercussion of the different 
biological processes involved in AD are not yet entirely clear. Though neurodegeneration, 
senile plaques, and NFTs are broadly accepted as part of the AD, it remains difficult to 
determine to what magnitude these factors contribute to dementia and to what magnitude 
they are interconnected with each other. However, some studies have shown that soluble 
oligomers of Aβ can disrupt synaptic function, facilitate neuronal dysfunction in AD, and 
are both essential and sufficient to disrupt learning behaviour in a way that is both potent, 
rapid, and transient 9.  
 
1.1.2. AD Forms 
There are two forms of AD: the familial form, which has an earlier onset (symptoms 
tend to develop before age 65), faster progression, and affects around 1% of the patients; 
and the sporadic form, which has a later onset (symptoms develop at age 65 or older), and 
is the most common condition. Nonetheless, the clinical and histopathological features of 
both forms are undistinguishable 1,3.  
The familial AD is caused by mutations in three genes: the amyloid precursor protein 
(APP) gene, and the presenilin genes, PSEN1 and PSEN2, which are involved in the cleavage 
of APP and production of Aβ 1,3. Mutations in the substrate and in the proteases can 
contribute to amyloid deposition, which forms one of the corner stones of the “amyloid 
hypothesis” 13. Mutations in the APP gene, on chromosome 21q21.3, are estimated to 
represent about 5% of familial AD. To date, a total of 51 mutations have been identified in 
the APP gene, but not all are pathogenic. Two well-studied mutations found in familial AD 
families have been expressed in transgenic mice. In the first case, the “London mutation”, 
a missense mutation, a valine is replaced by an isoleucine at codon 717 (V717I). In the 
second case, the “Swedish mutation”, where, immediately upstream of the Aβ domain, 
mutations at codons 670 and 671 resulted in a double base pair substitution, whereby a 
lysine and a methionine are replaced by aspartic acid and leucine (K670D/M671L, APPsw)  
14.  
Mutations in the PSEN1 gene, on chromosome 14q24.3, are the most common cause 
of autosomal dominant early-onset AD, accounting for up to 70% of cases 15, with about 
207 mutations identified in this gene. While in the PSEN2 gene, on chromosome 1q31-q42, 
only 25 mutations have been described so far, and not all have been confirmed to be 
pathogenic, accounting for less than 5% of early-onset AD cases 16,17. Mutations in PSEN1 
and PSEN2 genes result in the production of abnormal presenilin (PS) proteins, which 
interfere with the γ-secretase complex function, mainly due to a defective PS1. 
Consequently this alters APP processing, because PS/γ-secretase can cleave APP at 
different positions. That leads to variable effects on the spectrum of Aβ peptides released, 
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which are the overproduction of the longer and toxic version of Aβ peptides (≥Aβ42) and 
the underproduction of the shorter version of Aβ peptides (≤Aβ40). Copies of the toxic 
peptide fragment stick together and build up in the brain, forming the senile plaques 13. 
The MAPT gene is located on chromosome 17q21.1, and codes for human 
microtubule-associated protein Tau 18. No mutations have been identified in familial AD. 
However, exonic and intronic mutations were identified in the Tau gene that were 
associated to frontotemporal dementia with parkinsonism-17, a familial dementia related 
to AD. These findings prove that dysfunction of Tau in itself can cause neurodegeneration 
and consequently contribute to dementia. Besides frontotemporal dementia, Tau 
mutations can cause diseases as varied as subcortical gliosis, cortico-basal degeneration 
and pallido-ponto-nigral degeneration 14. 
 
1.1.3. AD Risk Factors 
AD is a complex multifactorial disease attributable to various interrelated and 
interacting environmental and genetic factors. Many factors contribute to the 
development of AD. Advanced age is the greatest risk factor for AD, but this disease is not 
a typical part of ageing. Another risk factor is the family history, because individuals who 
have a first-degree relative with AD are more likely to develop the disease than those who 
do not. People with mild cognitive impairment (MCI), especially MCI involving memory 
problems, are more likely to develop dementia than people without it. Cardiovascular 
diseases and factors that increase the risk of cardiovascular diseases, like smoking, alcohol 
intake, high body mass index, diabetes mellitus, high cholesterol, and hypertension, are 
also associated with a higher risk of developing AD and other dementias. A healthy heart 
and healthy blood vessels help ensure that the brain is supplied with the oxygen- and 
nutrient-rich blood, required for normal brain function. Apolipoprotein E gene (APOE) is 
one of the genetic risk factors for AD, and is associated with sporadic AD. The APOE gene, 
on chromosome 19q13.2, has three allelic variants, ε2, ε3 and ε4, and studies suggest that 
the ε3 allele neither increases nor decreases one’s risk of AD, but having the ε2 allele may 
decrease one’s risk. However, having the ε4 allele increases the risk of developing AD and 
of developing it at a younger age. People who inherit two copies of the ε4 allele have an 
even higher risk of developing AD, although inheriting the ε4 allele does not guarantee that 
a person will develop this illness 3,19. 
On the preventive side, physical activity and consumption of a diet low in saturated 
fats and rich in fruits, vegetables and vegetable-based oils are two factors that protect the 
heart as well the brain and reduce the risk of developing dementia. Other protective factors 
are education, and social and cognitive engagement. This can be explained by the fact that 
having more years of education, and remaining socially and cognitively active builds a 
“cognitive reserve”. According to this hypothesis, having more years of education, and 
 7 
remaining socially and cognitively active increases the connections between neurons in the 
brain and empowers the brain to compensate more fully for the early brain changes of AD 
or other dementias by using alternative routes of neuron-to-neuron communication to 
complete a cognitive task 3,19. 
 
 
 APP 
APP is evolutionary highly conserved and it´s family includes the mammalian amyloid 
precursor-like protein (APLP) 1 and 2, the Drosophila melanogaster β-amyloid-like protein 
APPL, and the Caenorhabditis elegans β-amyloid-like protein APL-1 (reviewed in Jacobsen 
and Iverfeldt, 2009 20).  
All APP family members are type 1 integral transmembrane (TM) glycoproteins, and 
are composed by a large ectoplasmic amino-terminal (N-terminal) region, a single 
membrane-spanning domain, and a shorter cytoplasmic carboxy-terminal (C-terminal) 
region 21,22 (reviewed in Jacobsen and Iverfeldt, 2009 20). The APP sequence can be divided 
into several distinct domains, as demonstrated in Figure 2. The ectoplasmic region of APP, 
which represents the larger part of the protein, can be divided into the E1 and E2 domains. 
The E1 domain can be further divided into a number of subdomains, including a heparin-
binding/growth-factor-like domain (HFBD/GFLD), a copper-binding domain (CuBD) and a 
zinc-binding domain (ZnBD). The E1 domain is followed by an acidic region rich in aspartic 
acid and glutamic acid (DE) and a Kunitz protease inhibitor domain (KPI), which is not 
present in APP695 (an APP alternatively spliced isoform). The E2 region consists of another 
HFBD/GFLD and a random coil (RC) region. The cytoplasmic region of APP contains a protein 
interaction motif, namely the YENPTY sequence (including the NPXY internalization signal), 
which is conserved in all APP homologues. The sequences of all APP homologues can be 
divided into similar domain structures as APP (Figure 2) (reviewed in Jacobsen and Iverfeldt, 
2009 20).  
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Figure 2: Schematic diagram of APP and its homologues domain organization. 
All APP family members are type I integral membrane proteins that have relatively large extracellular domains 
and short intracellular domains. They contain heparin-binding/growth-factor-like domains (HBD/GFLD), 
copper- and zinc-binding domains (CuBD and ZnBD), an acidic domain (DE), and a protein interaction motif 
(YENPTY) in the carboxy-terminal. Other abbreviations: APL-1, Caenorhabditis elegans β-Amyloid-Like 
Protein; APLP, Amyloid Precursor-Like Protein; APP770, an Amyloid Precursor Protein alternatively spliced 
isoform; APPL, Drosophila melanogaster β-Amyloid-Like Protein; Aβ, β-Amyloid Peptide; KPI, Kunitz Protease 
Inhibitor Domain; RC, Random Coil (adapted from 20). 
 
APP is ubiquitously expressed and is encoded by a single gene on chromosome 
21q21.3. However, APP exists in 11 isoforms produced by alternative splicing of three exons 
in a 19-exon gene, of which exons 7, 8 and 15 can be alternatively spliced 23, and the 
different isoforms can be preferentially expressed in different cell types 20. There are three 
major isoforms of APP in mammals: APP695 (exons 1–6, 9–18), APP751 (exons 1–7, 9–18), 
and APP770 20,23. The main difference between APP isoforms is the presence or absence of 
the KPI domain and a chondroitin sulphate glycosaminoglycan (CS GAG) attachment site. 
The APP695 isoform is mainly found in cells of neuronal origin 20, while APP751 and APP770 
are the predominant isoforms expressed in non-neuronal cells 24. In mouse the presence of 
three APP splicing forms (APP695, APP751, and APP770) was described, the tissue 
distributions of these three forms are similar to that seen in humans 25,26.  
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1.2.1. APP Proteolytic Processing 
There are two proteolytic processing pathways of APP, the nonamyloidogenic 
pathway, and the amyloidogenic pathway, represented in Figure 3. Both pathways are 
mediated by at least three cleavage events. The nonamyloidogenic processing of APP is 
initiated through cleavage by α-secretase, which leads to the release and secretion of the 
soluble N-terminal ectodomain sAPPα from the cell surface leaving an 83 a.a. long C-
terminal membrane-bound fragment (C83). This fragment can be further processed by γ-
secretase, leading to the release and secretion of a small non-pathogenic peptide p3 and a 
free APP intracellular domain (AICD). In the amyloidogenic pathway, APP is initially cleaved 
by β-secretase and releases the large soluble N-terminal ectodomain sAPPβ. The remaining 
C-terminal stub of 99 a.a. (C99) can then be further processed by γ-secretase, in a similar 
way to the nonamyloidogenic pathway, generating Aβ and AICD. The AICD can be 
translocated into the nucleus, where it may function as a transcription factor. Aβ is a 
normal soluble cellular metabolite encompassing two main forms with different C-terminal 
regions, Aβ40 and Aβ42 20,23. 
γ-Secretase cleavage between Val711 and Ile712 (in the APP770 isoform) generates 
Aβ40, and cleavage between Ala713 and Thr714 results in production of Aβ42. After γ-
secretase cleavage, the remaining C-terminal fragments are 57 or 59 a.a. long (C57 and 
C59), and have been identified as AICD. Consequently, the final processing step has been 
suggested to be a result of three cleavage events. The C99 fragment is first cleaved at the 
ε-site between Leu720 and Val721, followed by cleavage at the ζ-site at the Val717-Ile718 
bond, and finally the peptide is cut at the γ-site 8,20. 
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Figure 3: Schemes of the amyloid precursor protein (APP) and its two proteolytic processing pathways and 
principal proteolytic derivatives. 
A) The largest of the known APP alternative splice forms, APP770, comprising 770 amino acids (a.a.). Regions 
of interest: a) a 17-residue signal peptide occurs at the N-terminal; b) two alternatively spliced exons of 56 
and 19 a.a. are inserted at residue 289; the first contains a serine protease inhibitor domain of the Kunitz 
type (KPI); c) a single transmembrane domain (TM) at a.a. 700–723. The β-amyloid peptide (Aβ) includes 28 
residues just outside the membrane plus the first 12–14 residues of the TM. B) The a.a. sequence within APP 
that contains the Aβ and TM regions. The underlined residues represent the Aβ42 peptide. Three-digit 
numbers represent codon numbers (APP770 isoform). C) The nonamyloidogenic pathway. The first arrow 
indicates a site (after residue 687; same as white dot in Aβ box in A) of cleavage by α-secretase that enables 
secretion of the large, soluble ectodomain sAPPα into the medium and retention of the 83-residue C-terminal 
fragment (C83) in the membrane. C83 can undergo cleavage by γ-secretase principally at residue 711 or 
residue 713 to release the p3 peptides. D) The amyloidogenic pathway. The alternative proteolytic cleavage 
after residue 671 by β-secretase that results in the secretion of the slightly truncated sAPPβ molecule and 
the retention of a 99-residue C-terminal fragment in the membrane. C99 can also undergo cleavage by γ-
secretase to release the Aβ peptides. Cleavage of both C83 and C99 by γ-secretase at the ε-site (in B) releases 
the APP intracellular domain (AICD) into the cytoplasm. The order and interdependency of the γ- and ε-
cleavages have not been established (adapted from 8). 
 
Although APP processing has been widely studied, all the processing events and the 
enzymes involved have not yet been fully elucidated.  
 
a) α-Secretase 
α-Secretase is a zinc metalloproteinase that cleaves APP at the Lys687-Leu688 bond 
(in the APP770 isoform) 8,20, and metabolizes about 90% of APP 9. Several enzymes can act 
as α-secretase, and they are all members of the ADAM (A Disintegrin And Metalloprotease) 
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family. The enzymes are ADAM9, ADAM10 and ADAM17, also known as tumour necrosis 
factor-α converting enzyme (TACE) 9,20. ADAMs are type 1 integral membrane proteins, 
~750 a.a. long, with a multidomain structure, including signal peptide, pro-domain, 
catalytic metalloprotease domain, disintegrin/cystein-rich domain, TM domain, and a short 
cytoplasmic domain 20, represented in Figure 4. All members of this family have four 
potential functions: cell fusion, cell adhesion, intracellular signalling and proteolysis 23. 
Apparently, they have redundant α-secretase cleavage activities but differential expression 
patterns 9.  
 
Figure 4: Structure of α-secretase. 
Processing of APP by α-secretase is mediated by a series of proteases, mostly members of the ADAM (A 
Disintegrin And Metalloprotease) family, which are all membrane bound and consist of several extracellular 
domains, including a signal peptide (SP), a pro-domain (Pro), a catalytic metalloprotease domain, a disintegrin 
domain (which in some instances provides interaction with integrin receptors), and a cysteine-rich domain. 
Other abbreviations: TM, Transmembrane (adapted from 27). 
 
b) β-Secretase 
The APP cleavage at the Met671-Asp672 bond (in the APP770 isoform) is carried out 
by β-secretase (Figure 5), an aspartyl protease, which constitutes the first step towards Aβ 
generation. BACE (β-Site Amyloid Precursor Protein-Cleaving Enzyme) 1 and BACE2 are the 
two β-secretases that have been identified. BACE is a single domain integral protein with 
the active site located on the ectoplasmic side of the membrane. The optimal pH of BACE 
activity is approximately 4.5, indicative that the β-site cleavage of APP takes place in the 
more acidic cellular compartments, like the endosomes. BACE cleavage has also been 
proposed to occur in lipid rafts (reviewed in Jacobsen and Iverfeldt, 2009 20). BACE1 is 
widely expressed in the brain 20, particularly in the neurons 9.  
 
Figure 5: Structure of β-secretase. 
β-Secretase activity is specifically mediated by the β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 
(BACE1). BACE1 is a membrane-bound enzyme that is synthesized with a signal peptide (SP), a pro-domain 
(Pro), and a catalytic domain. Other abbreviations: TM, Transmembrane (adapted from 27). 
 
c) γ-Secretase 
γ-Secretase is an aspartyl protease, with a low sequence specificity that cleaves the 
substrate within its TM domain. The protein is a complex holoenzyme that consists of 
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several individual enzymes, including PS1 or PS2, anterior pharynx defective 1 (Aph-1), 
nicastrin, and presenilin enhancer 2 (Pen-2), as demonstrated in Figure 6. The 
stoichiometry (proportions in which elements are combined) of the γ-secretase 
components is likely 1:1:1:1, but was also suggested the possibility that also larger 
multimers are formed or that additional proteins are incorporated into the complex. PS is 
a polytopic protein with nine TM domains, and is considered to possess the active site of 
the enzyme. The core of the catalytic site of PS consists of two highly conserved aspartate 
residues (Asp257 and Asp385 in human PS1) within TM6 and TM7. Nicastrin is an 
evolutionarily conserved type I integral membrane protein that is highly glycosylated. This 
protein has one TM and a large ectodomain, proposed to function as a gate keeper to the 
PS1 active site, restricting access of substrates to the complex. Nicastrin also functions as a 
substrate receptor and is important for the assembly process of the γ-secretase complex. 
Aph-1 has a seven TM structure with the C-terminal located in the cytoplasm. Pen-2 
displays a hairpin-like structure with two TM domains and both termini located at the 
luminal side. The functions of Aph-1 and Pen-2 are not yet completely understood. Still, 
Aph-1 has been implicated in stabilization of PS1 and plays a significant role during 
assembly of the complex. Additionally, Pen-2 stabilizes the final complex and is involved in 
endoproteolysis of PS1 13,20.  
PS/γ-secretase cleaves with remarkable relaxed sequence specificity TM domains of 
several proteins, like APP, APLP-1, APLP-2, Notch 1, 2, 3 and 4, among others (reviewed in 
Wakabayashi and De Strooper, 2008 13). It is essential that the substrates have a type I 
conformation of the TM domain and a very short (<50 a.a.) extracellular ectodomain 28,29. 
Bulky extracellular ectodomains greater than 200-300 a.a. residues prevent γ-secretase 
cleavage and are usually removed by membrane bound (metallo)-proteases or “sheddases” 
at the cell surface. This first cleavage can be triggered by ligand binding, as is the case for 
Notch, whereas for other substrates, e.g., APP, shedding is largely constitutive. γ-Secretase 
cleavage occurs at different positions in the membrane domain of its substrates, generating 
a series of small peptides, like Aβ or p3, and AICD (APP), Nβ and NICD (Notch), etc., which 
are secreted at the extracellular side of the membrane (reviewed in Wakabayashi and De 
Strooper, 2008 13).  
Both PS proteins (PS1 and PS2) share approximately 63% homology with the highest 
similarity in the TM domains, where most of the familial AD-linked mutations are found 
(reviewed in Parent and Thinakaran, 2010 30). Both PS have been targets of intense study. 
Knockouts, knockins, and transgenic models have been used to study these proteins 9.  
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Figure 6: Scheme of the γ-secretase complex. 
γ-Secretase is a highly hydrophobic complex composed of four integral membrane proteins: presenilin 
enhancer 2 (Pen-2), presenilin (presenilin 1 or presenilin 2), nicastrin, and anterior pharynx defective 1 (Aph-
1). Presenilin 1 and presenilin 2, and Aph-1a and Aph-1b are encoded by different genes, and all subunits can 
combine to generate at least four different complexes. Alternative splicing of these genes adds further 
complexity. Presenilin provides the active site with two catalytic aspartates located in transmembrane (TM) 
domains 6 and 7 (indicated as stars). Nicastrin and Aph-1 first form a stable subcomplex, followed by 
incorporation of presenilin and Pen-2 in the early secretory compartment. Once all four components 
assemble, presenilin undergoes endoproteolysis by unknown “presenilinase” activity within the large 
intracellular loop between TM6 and TM7 (indicated by an arrow), and the amino-terminal fragment (NTF) 
and the carboxy-terminal fragment (CTF) remain noncovalently bound. Only fully assembled complexes reach 
the cell surface and endocytic compartments (adapted from 13). 
 
1.2.2. APP Functions  
Despite all the findings with respect to APP and its homologues, its biological 
functions are still not fully understood, and will require further research in the future. It is 
clear that proteins from the APP family have redundant and partially overlapping functions, 
and their biological functions are not restricted to the nervous system. Several in vitro and 
in vivo studies suggest that APP, APLP1, and APLP2 are involved in the developing and adult 
nervous system, cell adhesion and migration, neurite outgrowth, neuronal survival and 
apoptosis, synaptogenesis, vesicular transport, neuronal migration, modulation of synaptic 
plasticity, axonal transport, and can act as modulators of insulin and glucose homeostasis. 
In particular, APP functions as a cell surface receptor and is involved in transcription 
regulation through protein-protein interactions (reviewed in Jacobsen and Iverfeldt, 2009 
20). 
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1.2.3. APP Post-translational Modifications 
The APP family proteins are post-translationally modified in several different ways. 
All family members undergo N-glycosylation within its extracellular domain. Both APP and 
APLP2 have been shown to be subject to O-glycosylation within its extracellular domain, 
sialylation, and CS GAG modification 20,24. Some post-translational modification sites are 
conserved in all homologues, like the APP N467 N-glycosylation site. Whereas others sites 
are only conserved within the mammalian homologues, like the APP K695 sumoylation site 
20. N-glycosylation affects the processing of APLP1, once when it’s blocked with tunicamycin 
additional APLP1 fragments are generated. However, the processing of APP and APLP2 was 
unaffected by the blocking of N-glycosylation 31. In contrast, sialylation affects APP 
processing, since overexpression of sialyltransferase enhanced secretion of Aβ 32. 
All APP family members have been shown to be phosphorylated, and some of the 
most studied phosphorylation sites are shown in Table 1. APP is a phosphoprotein that has 
several phosphorylatable a.a. residues in its intracellular and extracellular domains 20,24. 
Among the intracellular domain sites that can be phosphorylated, Thr654, Ser655, and 
Thr668 (numbering for the APP695 isoform) have been shown to be phosphorylated in 
adult rat brain 33,34. The Tyr653, Ser655, Thr668, Ser675, Tyr682, Thr686 and Tyr687 were 
found to be phosphorylated in post-mortem brain tissue of AD patients 35. Phosphorylation 
at these sites has been described to impact APP cellular localization. In addition, Thr668 
phosphorylated APP has been found to be enriched in endocytic compartments and to co-
localize with BACE in AD brains 35.  
Since these residues are located in specific protein interacting sites its 
phosphorylation may interfere with protein binding and thus interfere with APP and AICD 
functions. Additionally, some phosphorylation sites may affect the processing of APP 20. Lee 
et al. (2003) reported that Aβ production was reduced in rat embryonic cortical neurons 
when treated with a cyclin-dependent kinase (CDK) 5 inhibitor, which reduced Thr668 
phosphorylation, or when transfected with Thr668Ala mutant APP 35. In another study, 
Thr668 phosphorylation of APP was reported to induce increased β-cleavage, but 
decreased γ-cleavage, resulting in decreased Aβ production 36. Phosphorylation of APP at 
Tyr687 was suggested to regulate α-cleavage of APP since overexpression of the mutant 
Tyr687Ala decreased the level of the C83 fragment 37. 
Alignment of the APP family members shows that the APP Thr668 phosphorylation 
site is conserved in all APP homologues: APLP1 (Thr624), APLP2 (Thr736), APPL (Thr855), 
and APL-1 (Thr660). Three other in vivo phosphorylated sites in APP, Tyr682, Thr686, and 
Tyr687 (which are part of the YENPTY motif), are also conserved in all APP homologues. 
Tyr653, another in vivo phosphorylated site in APP, is conserved in both mammalian 
homologues, but not in APPL or APL-1 (reviewed in Jacobsen and Iverfeldt, 2009 20). 
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Table 1: Some of phosphorylation sites of APP and its homologues, and the different enzymes that mediate 
the phosphorylation. 
Phosphorylatable Amino 
Acid Residues 
Protein Kinase  
Thr654 and Ser655 (APP) CaMPK II 38 in vitro 
Ser655 (APP) PKC 38 in vitro 
Thr668 (APP) 
CDK1/CDC2 kinase 33 
in dividing cells, at the 
G2/M phase of the cell 
cycle  
JNK3 39 
during neuronal 
differentiation  
CDK5 40 and GSK-3β 41 in post-mitotic neurons 
JNK1 and JNK2 42 
in response to cellular 
stress  
Thr736 (APLP2 763 
isoform) CDC2 kinase 43 in vitro 
Abbreviations: APLP, Amyloid Precursor-Like Protein; APP, Amyloid Precursor Protein; CaMPK, 
Calcium/Calmodulin-dependent Protein Kinase; CDC, Cell Division Cycle; CDK, Cyclin-Dependent Kinase; GSK, 
Glycogen Synthase Kinase; JNK, c-Jun N-terminal Kinase; PKC, Protein Kinase C; Ser, Serine; Thr, Threonine. 
Residue in bold type was the one addressed in this study. 
 
APP phosphorylation has been shown to regulate intracellular signaling via adaptor 
proteins. Thr668 phosphorylation was shown to induce large conformational changes of 
the intracellular domain 44. It was later shown that the peptidyl-, prolyl cis/trans isomerase 
Pin1 binds to Thr668-phosphorylated APP both in vitro and in vivo and thereby accelerates 
the production of the trans conformation of Pro669 45. This proline residue is conserved in 
APLP2 (Pro737) and APL-1 (Pro662), but not in APLP1 or APPL. It was further demonstrated 
that the Pin1-catalysed isomerization of APP regulated its processing, since overexpression 
or knockout of Pin1 reduced or increased the secretion of Aβ, respectively. It has further 
been shown that Pin1 knockout in mice resulted in age-dependent neuropathy 46.  
 
 
 Tau 
Tau protein regulates MT assembly, dynamic behaviour, and spatial organization 
under physiological conditions 47,48. Tau protein has been shown to regulate axonal 
transport of organelles, including mitochondria 49. Proteins from the MAP family are 
present in several species, such as C. elegans 50,51, Drosophila 52,53, goldfish 54, bullfrog 55, 
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rodents 56,57, bovines 58,59, goat 60, monkeys 60, and human 61,62. In human, MAPs are mainly 
present in neurons 63, although non-neuronal cells usually present trace amounts. For 
example, glial cells express Tau protein mainly in pathological conditions 64, and it is 
possible to detect Tau mRNA and proteins in several peripheral tissues like heart, lung, 
kidney, pancreas, testis, muscle, and fibroblasts 65–67. 
The gene encoding human Tau protein MAPT is unique and located on chromosome 
17q21.1 68, spans approximately 150 kb, and contains 16 exons 69 (Figure 7). The exons 4A, 
6 and 8 are speciﬁc to peripheral Tau protein, therefore are never present in any mRNA of 
human brain 58,60. Tau is encoded by a single gene from which nine isoforms are produced 
through alternative splicing 70, six of which (range from 352 to 441 a.a. and an apparent 
molecular weight of 48–67 kDa) are the isoforms expressed in human central nervous 
system (CNS) 61,62,71.  
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Figure 7: Schematic representation of the human Tau gene, the human Tau primary transcript and the six 
human central nervous system (CNS) Tau isoforms. 
The human Tau gene is located over 100kb on chromosome 17q21.1. It contains 16 exons, with exon -1 being 
part of the promoter (upper panel). Tau primary transcript contains 13 exons, since exons 4A, 6 and 8 are not 
transcribed in human brain (middle panel). Exons -1 and 14 are transcribed but not translated. Exons 1, 4, 5, 
7, 9, 11, 12, 13 are constitutive, and exons 2, 3, and 10 are alternatively spliced, giving rise to six different 
mRNAs, translated in six different CNS Tau isoforms (lower panel). These isoforms differ by the absence or 
presence of one or two 29 amino acids (a.a.) inserts encoded by exon 2 (yellow box) and 3 (green box) in the 
amino-terminal part, in combination with either three (R1, R3 and R4) or four (R1–R4) repeat-regions (black 
boxes) in the carboxy-terminal part. The fourth microtubule-binding domain is encoded by exon 10 (light blue 
box) (lower panel). The adult Tau isoforms include the longest 441-a.a. component (2+3+10+), the 410-a.a. 
component (2+3+10-), the 412-a.a. component (2+3-10+), the 381-a.a. component (2+3-10-) and the 383-a.a. 
component (2-3-10+). The shortest 352-a.a. isoform (2-3-10-) is found only in the foetal brain, and thus is 
referred as foetal Tau isoform (adapted from 72). 
 
Tau can be subdivided into four regions (Figure 8): i) an acidic region in the N-terminal 
part; ii) a proline-rich region; iii) a region responsible for binding with MTs (MT-binding 
domains); and iv) a C-terminal region 73. There are two aspects that separate Tau isoforms, 
these are: the absence or presence of one or two inserts (29 or 58 a.a.) in the N-terminal 
part of the molecule; and the presence of either three or four repeat-regions in the C-
terminal part (3R and 4R Tau), an outcome of alternative splicing of exon 10 58,61,62,74. There 
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is evidence that each of these isoforms may have particular biological roles, once they are 
differentially expressed during development. For example, the only Tau isoform present 
during foetal stages is the one characterized by the absence of N-terminal inserts and the 
presence of three C-terminal repeats, 3R Tau (exons 2, 3 and 10 are spliced out). Adult 
human CNS expresses equal amounts of 3R and 4R isoforms (with one or two N-terminal 
inserts and three or four C-terminal repeats). These findings demonstrate developmental 
regulation of exon 10 splicing 75,76. Therefore, it is highly probable that Tau isoforms have 
speciﬁc functions related to the absence or presence of regions encoded by the cassette 
exons 2, 3 and 10. Moreover, the relative levels of six Tau isoforms expressed in adult 
human CNS (3R and 4R isoforms) differ between neurons in different brain regions. 
Granular cells of the dentate gyrus (hippocampal formation) don’t express Tau mRNAs 
containing exon 10 (4R Tau), only 3R Tau 61,62. Tau isoforms may be differentially distributed 
in neuronal subpopulations 72.  
 
Figure 8: Schematic representation of the functional domains of the longest Tau isoform (2+3+10+). 
The projection domain, including an acidic and a proline-rich region, interacts with neural plasma membrane 
and cytoskeletal elements to determine spacings between microtubules in axons. The amino-terminal part is 
also involved in signal transduction pathways by interacting with proteins as phospholipase C-γ (PLC-γ) and 
Src-kinases. The carboxy-terminal part, referred to as microtubules binding domain, regulates the rate of 
microtubules polymerization and stabilization. It is also involved in the binding with functional proteins as 
protein phosphatase 2A (PP2A) or presenilin 1 (PS1) (adapted from 72). 
 
1.3.1. Tau Phosphorylation  
The exons 9-12 of Tau gene encode four imperfect repeat domains (encompassing 
31–32 residues) that mediate the interaction between Tau and tubulin 77. Within neurons, 
Tau is predominantly found in axons 78 as a highly soluble phosphoprotein 79. Tau contains 
85 putative phosphorylation sites: 45 are serines, 35 are threonines and only 5 are tyrosines 
72,80,81. Most of these phosphorylation sites are on Ser-Pro and Thr-Pro motives 82. Table 2 
summarizes the four groups of protein kinases that can phosphorylate Tau: i) the Proline-
Directed Protein Kinases (PDPKs) which phosphorylate Tau on serine or threonine residues 
that are followed by a proline residue; ii) the non-PDPK group; iii) protein kinases that 
phosphorylate Tau on serine or threonine residues followed or not by a proline; iv) and the 
tyrosine protein kinases (reviewed in Buée et al., 2010 83).  
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Table 2: Most studied protein kinases involved in Tau phosphorylation (reviewed in 72,80). 
 
Abbreviations: CaMPK, Calcium/Calmodulin-Dependent Protein Kinase; CDC, Cell Division Cycle; CDK, Cyclin-
Dependent Kinase; CK, Casein Kinase; DYRK, Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase; 
GSK, Glycogen Synthase Kinase; MAPK, Mitogen Activated Protein Kinase; MARK, Microtubule-Affinity 
Regulating Kinase; MSK, Mitogen- and Stress-Activated Protein Kinase; PDPK, Proline-Directed Protein 
Kinases; PK, Protein Kinase; SAP, Stress-Activated Protein; TTBK, Tau-Tubulin Kinase. 
 
Tau binding affinity for MTs is regulated by the phosphorylation of serine and 
threonine residues 84,85. It is believed that through this binding, Tau plays a major role in 
stabilizing MTs. When phosphorylated, Tau protein is not able to polymerize tubulin into 
MTs and do not stabilize the latter 86. 
Tau’s phosphorylation process is also developmentally regulated. During 
embryogenesis and early development, when only the shortest of the isoforms is 
expressed, Tau phosphorylation reaches high levels. By contrast, adult brain expresses six 
isoforms with relatively reduced phosphorylation levels compared with the foetal situation 
87.  
PDPK
• Cyclin-Dependent Kinases including CDC2, CDK1 and CDK5;
• MAPK;
• SAP Kinases.
Non-PDPK
• CaMPK II;
• CK1, CK2 and CK1δ;
• DYRK1A;
• MARK;
• Phosphorylase Kinase;
• PKA, PKB, PKC and PKN;
• Rho kinase;
• TTBK1 and TTBK2.
Kinases that phosphorylate on Serine or Threonine residues followed or not by a Proline
• AGC kinases, such as MSK1 (recognition motifs RXRXXS/T);
• GSK-3α and GSK-3β (recognition motifs SXXXS or SXXXD/E).
Tyrosine Protein Kinases
• Src kinases;
• c-Abl;
• c-Met.
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The different levels of Tau phosphorylation are a dynamic process that results from 
the activity of several specific kinases (Table 3) and phosphatases (Table 4) towards specific 
sites.  
 
Table 3: Protein kinases involved in Tau phosphorylation and the respective phosphorylation sites (reviewed 
in 88). 
Protein Kinase Phosphorylation Sites 
PKA 
Ser195, Ser198, Ser199, Ser202, Thr205, Thr212, Ser214, Thr217, Thr231, 
Ser324, Ser235, Ser258, Ser262, Ser356, Ser409, Ser412, Ser413, Ser416, 
Ser422, Ser435 
PKB Thr212, Ser214 
PKC Ser258, Ser293, Ser324, Ser352 
PKN Ser214, Ser258, Ser320, Ser352 
RSK Thr212, Ser214 
MSK1 Ser214, Ser262, Ser305 
SGK1 Ser214 
p70S6K Thr212, Ser214, Ser262 
ROCK Thr245, Ser262, Thr377, Ser409 
p110 kinase Ser262 
CaMPK II Ser214, Thr217, Thr231, Ser235, Ser262, Ser396, Ser404 
AMPK Thr231, Ser262, Ser396, Ser404 
BRSK Ser262 
MARK 
Thr17, Thr95, Ser113, Ser131, Thr149, Thr169, Ser184, Ser198, Ser208, Ser214, 
Ser237, Ser238, Ser262, Ser320, Ser324, Ser356 
CK1 
Ser241, Ser258, Ser262, Thr263, Ser285, Ser289, Ser305, Ser341, Ser352, 
Ser356, Thr361, Thr373, Thr386, Ser412, Ser416, Ser433, Ser435 
TTBK1/2 Ser198, Ser199, Ser202, Ser208, Ser210, Ser422 
CDK5 
Thr181, Ser199, Ser202, Thr205, Thr212, Ser214, Thr217, Thr231, Ser235, 
Ser396, Ser404 
MAPK 
Ser46, Thr50, Thr153, Thr181, Ser199, Ser202, Thr205, Thr212, Thr217, Ser235, 
Ser396, Ser404, Ser422 
JNK Thr181, Ser199, Ser202, Thr205, Thr212, Thr217, Ser396, Ser404, Ser422 
CDC2 Thr153, Ser202, Thr205, Thr212, Thr231, Ser235, Ser404 
GSK-3β 
Ser46, Thr50, Thr181, Ser184, Ser199, Ser202, Thr205, Thr212, Ser214, Thr217, 
Thr231 
DYRK1A 
Thr181, Ser199, Ser202, Thr205, Thr212, Thr217, Thr231, Ser396, Ser400, 
Ser404, Ser422 
 21 
SAPK 
Thr50, Thr69, Thr153, Thr181, Ser199, Ser202, Thr205, Thr212, Thr217, Ser235, 
Ser396, Ser404, Ser422 
CK2 Thr39, Ser199, Ser396, Ser400 
Abbreviations: AMPK, Adenosine Monophosphate-Activated Protein Kinase; BRSK, Brain-Selective Kinase; 
CaMPK, Calcium/Calmodulin-Dependent Protein Kinase; CDC, Cell Division Cycle; CDK, Cyclin-Dependent 
Kinase; CK, Casein Kinase; DYRK, Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase; GSK, Glycogen 
Synthase Kinase; JNK, c-Jun N-terminal Kinase; MAPK, Mitogen Activated Protein Kinase; MARK, Microtubule-
Affinity Regulating Kinase; MSK, Mitogen- and Stress-Activated Protein Kinase; p110 kinase, A 110 kDa 
Microtubule Affinity-Regulating Kinase; p70S6K, S6 Ribosomal Protein Kinase; PK, Protein Kinase; ROCK, Rho-
Associated, Coiled-Coil-Containing Kinase; RSK, Ribosomal Protein S6 Kinase; SAPK, Stress-Activated Protein 
Kinase; Ser, Serine; SGK, Serum- and Glucocorticoid-Regulated Kinase; Thr, Threonine; TTBK, Tau-Tubulin 
Kinase. Residues in bold type were the ones addressed in this study. 
 
Table 4: Protein phosphatases involved in Tau dephosphorylation and the respective dephosphorylation sites 
(reviewed in 88). 
Protein 
Phosphatase 
Dephosphorylation Sites 
PP1 
Ser198, Ser199, Ser202, Thr212, Thr217, Ser262, Ser396, Ser404, 
Ser422 
PP2A 
Ser46, Ser198, Ser199, Ser202, Ser205, Thr217, Thr231, Ser262, 
Ser396, Ser404, Ser422 
PP2B  
(calcineurin) 
Ser46, Thr181, Ser199, Ser202, Thr217, Ser235, Ser262, Ser356, 
Ser396, Ser404, Ser422 
PP5 
Ser198, Ser199, Ser202, Thr231, Ser235, Ser262, Ser356, Ser396, 
Ser404, Ser422 
Abbreviations: PP, Serine/Threonine Protein Phosphatase; Ser, Serine; Thr, Threonine. Residues in bold type 
were the ones addressed in this study. 
 
In addition to being phosphorylated, Tau can be O-GlcNAcylated, nitrated, and 
ubiquitinated 89.  
 
1.3.2. Tauopathies  
Tauopathies are a class of neurodegenerative disorders, that include AD, and are 
characterized by the presence of aggregates of abnormally phosphorylated Tau in the CNS 
89–93. In tauopathies, the natively unfolded Tau protein forms intracellular fibrillar 
structures of aggregated, hyperphosphorylated, and ubiquitinated Tau, which are 
associated with synaptic and neuronal loss. Upon abnormal phosphorylation, Tau reduces 
its affinity for and dissociates from MTs 94–96. In AD brains Tau accumulates as paired helical 
filaments (PHF) in the neuronal perikarya and processes 97,98. It has been proposed that at 
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the single-cell level the defects start with a modification of Tau by phosphorylation, causing 
destabilization of MTs and consequently resulting in a “pre-tangle” stage 99. After this stage, 
the destabilization of MTs leads to loss of dendritic MTs and synapses, plasma membrane 
degeneration, and finally cell death 100.  
Occurrence of fibrillar Tau inclusions in tauopathies strongly supports a key role in 
the observed clinical symptoms and pathology. Interestingly, Tau is required for Aβ’s 
toxicity both in vitro and in vivo. This was suggested by the resistance shown by primary 
cultured neurons from Tau knockout mice when exposed to Aβ 101 as well as by the rescuing 
premature mortality and preventing memory deficits observed in APP transgenic mice 
when crossed with Tau knockout mice 102. This supports a central role of Tau in mediating 
Aβ toxicity in the early pathogenesis of AD 103.  
 
 
 Spermatogenesis 
Spermatogenesis is a dynamic and multistep process of male germ cell proliferation 
and differentiation by which spermatozoa are produced from primordial germ cells (PGCs) 
104. This process in mammals is controlled by a complex system of paracrine and endocrine 
activity within a structurally well-organized tissue 105.  
The formation of sperm begins with the embryonic PGCs migrating into the 
undifferentiated gonad as a response to soluble stem-cell factor. PGCs then differentiate 
into prospermatogonia and stay in a quiescent state within the testicular seminiferous 
tubules. At the onset of puberty, gonadotropic stimulation induces spermatogenesis (the 
meiotic divisions by which spermatogonia develop into sperm; Figure 9) followed by 
spermiogenesis (the differentiation of haploid round spermatids into flagellated sperm 
cells; Figure 10) 106. The mammalian process of spermatogenesis comprises three phases 
of cellular events, which are: i) the proliferative phase (spermatogonia), in which diploid 
spermatogonial germ cells divide by mitosis producing new germ cells, to maintain the 
germ cell pool, and committed cells (primary spermatocytes); ii) the meiotic phase 
(spermatocyte), in which primary spermatocytes undergo meiosis, reducing both the 
chromosome number and amount of deoxyribonucleic acid (DNA), and producing haploid 
daughter spermatids; iii) spermatid phase (spermiogenesis), in which spermatids undergo 
huge morphological and biochemical changes differentiating into mature sperm cells 
(spermatozoa) 105,107,108. Methylation of imprinted genes occurs between the 
spermatogonial and the spermatocyte phases. During the last stage of spermiogenesis, the 
nucleus flattens and condenses, as nonhistone basic proteins such as protamines displace 
the typical histones that associate with nuclear DNA, transcriptional activity in the 
spermatid is silenced, and nucleosomal structure is lost. At the same time, the remaining 
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cytoplasm is jettisoned as a “cytoplasmic droplet” 106. The resulting sperm cells ultimately 
separate from the adherent Sertoli cells and, once released into the lumen of the 
seminiferous tubule, passively migrate to the epididymis for further maturation 105. These 
maturation processes are required for fully functional spermatozoa (capable of motility and 
fertilization). Sperm cells are stored until they are ejaculated from the male reproductive 
tract. By the last stages of spermiogenesis, when sperm are released into the lumen of the 
seminiferous tubule, their ribosomes are nearly absent, and their endoplasmic reticulum 
has been lost from the cytoplasm. Given that they have no machinery to produce proteins, 
all of the factors that sperm will require for ascending the female reproductive tract must 
either be synthesized in advance and stored or must be provided from the outside – for 
example, by the cells of the cauda epididymis 106. 
 
Figure 9: Schematic representation of part of a seminiferous tubule with its surrounding cells.  
The seminiferous epithelium is formed by two cell populations: the cells of the spermatogenic lineage and 
the Sertoli cells (supporting cells). Surrounding the seminiferous tubule there is a layer of myoid cells, as well 
as connective tissue, blood vessels and interstitial cells. 1) Nearest the basement membrane are 
spermatogonia (diploid cells, 2n), which divide by mitosis to produce more germ cells and cells committed to 
meiosis (primary spermatocyte). 2) Primary spermatocytes replicate their deoxyribonucleic acid (DNA) shortly 
after they form and before meiosis begins, resulting in 2n 4d primary spermatocytes. Haploid secondary 
spermatocytes (1n 2d) are the result of the first meiotic division. 3) The secondary spermatocytes divide 
quickly again in the second meiotic division (no DNA replication precedes meiosis II) to become haploid 
spermatids (1n 1d). 4) These latter cells differentiate as sperm cells (spermiogenesis) that will be motile. 
These last events take place near the apical ends of the Sertoli cells at the lumen of the seminiferous tubules. 
Usually all stages of this process (spermatogenesis) do not take place within one small area of tubule as shown 
schematically here (adapted from 109,110). 
 
Central to this system are the Sertoli cells (also called supporting or sustentacular 
cells), which in response to endocrine and paracrine stimulation by factors such as follicle 
stimulating hormone (FSH) and luteinizing hormone (LH)-stimulated testosterone provide 
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both paracrine regulation and structural support to the differentiating germ cells. Sertoli 
cells adhere to germ cells to form a highly complex epithelium, in which various tight and 
adherent junctions form the blood-testis-barrier and regulate germ cell location and 
movement toward the lumen during differentiation. As secretory cells, Sertoli cells produce 
growth and anti-apoptotic factors such as Steel (kit-ligand), as well as seminiferous tubule 
fluid with its proteins and other constituents. Sertoli cells also have the function of 
phagocytosis of the degenerating germ cells and the residual body (excess cytoplasm) that 
remains from the released sperm. These supporting cells are essential to control the 
diverse environmental niches in which male germ cells develop 105,111. Leydig cells 
(interstitial cells), other specialized cell type that also support spermatogenesis, are in the 
interstitial tissue of the testis, and are uniquely positioned to provide testosterone to the 
seminiferous tubules to drive spermatogenesis 108. 
Sperm morphogenesis is accomplished inside the testis, but testicular sperm remain 
physiologically “immature”. During transit, mammalian sperm undergo epididymal 
maturation, but they remain unable to fertilize oocytes. Capacitation, the final preparatory 
step, occurs only when sperm have resided in the female genital tract for some time. This 
ill-defined process appears to be necessary for sperm to undergo a further morphological 
and physiological transition, the acrosome reaction, once they encounter the zona 
pellucida of the egg. The acrosome, a caplike structure covering the anterior portion of the 
sperm nucleus, contains multiple hydrolytic enzymes that are released by exocytosis prior 
to fertilization. Simultaneously, extensive changes occur in all sperm compartments (head 
and flagellum, membrane, cytosol, and cytoskeleton). Factors originating from epididymal 
fluid and seminal plasma are lost or redistributed, membrane lipids and proteins are 
reorganized, and complex signal-transduction mechanisms are initiated 106. 
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Figure 10: Spermiogenesis diagram.  
Major morphological changes occur within spermatids as they undergo the differentiation process and 
become highly specialized sperm cells. These changes involve flattening of the nucleus, formation of an 
acrosome which resembles a large lysosome, growth of a flagellum (tail) from the basal body, reorganization 
of the mitochondria in the midpiece region, and shedding of unneeded cytoplasm as a residual body (taken 
from 110). 
 
Humans vs. Rodents 
Like in AD research, rodent (rat, mouse and hamster) models are also used in studies 
of gametogenesis. Despite both being mammals, there are several differences between 
humans and rodents spermatogenesis and testes. In Table 5 some characteristics that 
differentiate between human and the species addressed in this study (rat and mouse) are 
indicated. Spermatogonia, which constitute the first phase, are the most immature 
spermatogenic cells and reside on the basement membrane of the seminiferous 
epithelium. These cells are classified into three types in humans and four types in rodent, 
based on the appearance of the nuclei (presence and distribution of heterochromatin) 
107,111. The human types are: type A dark spermatogonia; type A pale spermatogonia; and 
type B spermatogonia 107. The rodent types are: undifferentiated type A spermatogonia (A 
single, A paired, A aligned); differentiated type A spermatogonia (A1, A2, A3, A4); 
intermediate spermatogonia (In); and type B spermatogonia (B) (Table 5). However, 
presently, it is not possible to identify spermatogonial germ cells by routine microscopy, 
only by electron microscopy 111. 
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Table 5: Characteristics that differentiate spermatogenesis and testes of humans and rodents, which are 
constant and specific in each species. 
 Humans 
Rodents 
Rat Mouse 
Number of cycles of 
the seminiferous 
epithelium 
4.6 107 4.5 111 
Cycle lengths 16 days 107 12.9 days 112 8.6-8.9 days 111 
Duration to 
complete the 
spermatogenesis 
74 days 107 58 days 39-40 days 111 
Spermatogonial 
generations 111 
2 (Apale, B) c 
6 (A1-4, In, B) 
c 
6 (A1-4, In, B) c 
Meiotic index a 111 1.3 (68%) d 3.4 (15%) d 2.3-3.1 (23-43%) d 
Overall rate of 
spermatogenesis b 
111 
3.2 (80%) d 97 (62%) d 44-84 (67-83%) d 
Sperm cell head  
(the black areas 
represent portions of the 
nucleus covered by the 
acrosome)    
Layers of peritubular 
myoid cells 113 
multiple (five till seven) one 
Other features 113 
higher proportions of testis 
occupied by nongerminal 
components such as tunic, 
interstitium, tubule 
boundary tissue and Sertoli 
cells 
higher proportions of 
parenchyma, seminiferous 
tubules, seminiferous epithelium 
and germinal cells in the rat testis  
a Meiotic Index: Number of spermatids formed per each primary spermatocyte.  
b Overall Rate of Spermatogenesis: Number of spermatids formed per each differentiated type A1 
spermatogonia. 
c Type A spermatogonia (A); intermediate spermatogonia (In); and type B spermatogonia (B). 
d Number in parentheses show the percentage of germ cell loss (apoptosis) based on the theoretical yield. 
 
Germ cell loss (apoptosis) occurs normally during spermatogenesis in all mammals, 
and play a critical role in determining total sperm output. Significant germ cell loss occurs 
during the spermatogonial phase, called “density-dependent regulation”. One explanation 
is that the degeneration is a homeostatic mechanism to limit germ cells to the number that 
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can be supported by available Sertoli cells. Apoptosis is also frequent during meiosis (Table 
5), especially in humans, and is probably related to chromosomal damage. In addition to 
apoptosis, missing generations of spermatocytes and spermatids in the seminiferous 
epithelium also contribute to the low efficiency of human spermatogenesis. Thus, humans 
are less efficient at sperm production than rodents. In conclusion, the greatest influences 
on germ cell production are the capacity for mitosis, and the number of generations of 
spermatogonial divisions, which will determine, at least in part, the number of cells that 
enter meiosis 111.  
 
 
 AD-related Proteins and Fertility 
Infertility is described as “the inability of a couple to conceive despite trying for a 
year” 114. It affects about 10 to 15% of the reproductive-age population 104,115, with 
approximately equal contributions from both genders 104. The causes of male and female 
infertility are multifactorial 104,114, with several nutritional, behavioural, environmental and 
genetic factors affecting fertility 104. Genetic abnormalities contribute to infertility with 
estimates reaching 50%, and just a small part is described. Infertility diagnoses are very 
descriptive and reflect the lack of understanding of the many and varied factors that 
regulate male and female gamete production, maturation, and function 114.  
Even with growing knowledge of the physiology of male and female reproduction and 
the availability of new diagnostic tools, the pathogenesis of testicular 116 and premature 
ovarian insufficiency 117 remain undefined for the majority of cases and this is denoted as 
“idiopathic infertility”. Idiopathic infertility is likely to have a genetic origin because the 
number of genes and proteins involved in gametogenesis is around thousands and only a 
small fraction of them have been identified and screened in infertile men and women 116.  
Similar to AD research, knockout models are also used in studies of gametogenesis, 
especially mouse models. Knowledge obtained from these models has helped elucidate 
both intrinsic and acquired infertility, and the findings seem to be applicable to humans 106.  
 
1.5.1. APP and Fertility 
Supporting the hypothesis that APP is fertility-related are the findings using the 
double APP and APLP2 knockout mice. Contrary to APP knockout mice and APLP2 knockout 
mice (that are viable, normal, healthy and fertile 118,119), the double APP and APLP2 
knockout mice show high levels of mortality within the first week after birth (80%), and the 
surviving animals mate poorly, despite apparent normal ovarian and testicular 
development 120. These findings suggest that these two proteins, that can substitute for 
 28 
each other functionally, are required for early postnatal development and may be involved 
in gametogenesis 120.  
APP’s three major isoforms in mammals (APP695, APP751 and APP770) are present 
in mouse oocytes, pre-implantation embryos, and post-implantation embryonic stages to 
the late embryonic period 121. In rat testis, mRNAs encode APP751 and APP770 isoforms 
(APP isoforms KPI-positive) 122. Shoji and Kawarabayashi (1990) described the presence of 
native APP in acrosomes and in growing flagella, and suggested that APP appears in the 
head and tail formation phase in spermatids 122. Beer et al. (1995) demonstrated that APP 
is highly expressed in follicle cells (ovary) and in soma and processes of Sertoli cells (testis), 
and at low levels in germ cells (testis) 123. Supporting the Shoji and Kawarabayashi (1990) 
findings is the study from the da Cruz e Silva group, which describes distinct distributions 
of the APP family members in human sperm. This study was performed using a battery of 
antibodies that detect APP-specific epitopes, or epitopes common with other APP family 
members, showing that in rat testis 47% of the mRNA is APP770, 20% is APP751, and 20% 
is L-APP752. Results also show that in human sperm, the tail main piece mainly expresses 
full-length APP KPI-positive, the mid-piece mainly expresses APLP2 variants KPI-positive, 
the equatorial region of the spermhead is likely to contain mainly KPI-containing APLP2 
variants, and the surface of the entire spermatozoon, with particular abundance on the 
head, contain plasma membrane APP and/or APLPs (Figure 11). According to the authors 
of this study, the presence of APP family members on the surface of the spermatozoa 
strongly suggest that these proteins may have a very important role in the sperm 
interactions with the matrix or the oocyte, and in other sperm-specific functions 124. 
 
 
Figure 11: Schematic representation of the amyloid precursor protein (APP) family members expression in 
the human sperm.  
Abbreviations: APLP, Amyloid Precursor-Like Protein; APP, Amyloid Precursor Protein; KPI, Kunitz Protease 
Inhibitor Domain (taken from 124). 
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1.5.2. Tau and Fertility 
Despite the fact that Tau knockout mice shown no overt phenotype or malformations 
125–127 (reviewed in Ke et al., 2012 103) and only when aged, did they develop behavioural 
impairments and motor deficits 128,129 (reviewed in Ke et al., 2012 103), there is evidence 
that this protein may be involved in spermatogenesis. Contrary to what was thought for a 
long time, Tau’s expression is not limited to the nervous system. Ashman et al. (1992) 
identified this protein in rat and bovine testis 130. Through immunohistochemistry (IHC), 
Tau was observed, in bull testis, in the spermatid manchette, a transient, cross-linked MT 
network of unknown function. As spermatid elongation begins, the manchette forms a 
sheath around the posterior aspect of the nucleus, but, by the completion of nuclear 
condensation, the manchette is largely disassembled. Tau immunoreactivity was also 
observed in late stage I spermatids prior to manchette formation. These findings suggest 
that Tau not only plays a structural role in the manchette, but may also have a function in 
manchette assembly 130. Recently, Inoue and colleagues (2014) showed the expression of 
Tau and its phosphorylation in testes of mice at 12 weeks of age. This study revealed, 
through IHC, that Tau phosphorylation was strongly detected in spermatocytes during 
meiosis, while the expression of acetylated tubulin was inversely weakened during the 
same stage. According to the authors, these results suggest that Tau phosphorylation 
contributes to spermatogenesis, particularly in meiosis 73. 
 
1.5.3. Other AD-related proteins and Fertility 
As previously described, the three ADAM proteins that can act as α-secretase and 
participate in the nonamyloidogenic proteolytic processing pathway of APP are ADAM9, 
ADAM10 and ADAM17 proteins. Results from these three proteins single knockout mice do 
not show that they are fertility-related. ADAM9 knockout mice are viable and show no 
apparent abnormalities. This knockout also does not show aberrant APP processing, 
indicating functional compensation by or redundancy with other proteases. ADAM17 
knockout models are lethal embryonically and show little similarity to Notch knockouts. 
ADAM10 deficient mice are also lethal embryonically and die early in embryogenesis 
showing major defects in development of the CNS and the vascular system with similar 
histological abnormalities as observed in Notch deficiency induced in mice. Conditional 
knockout experiments of ADAM10 in mice have demonstrated a key role in the formation 
of the brain cortex with aberrant neuronal differentiation in the null mice 131.  
BACE1 and BACE2 are two proteins that can act as β-secretase in the amyloidogenic 
pathway, as mentioned before. Like ADAM proteins, which can act as α-secretase, BACE 
proteins apparently are not fertility-related. BACE1 132,133 and BACE2 133 single knockout 
mice are viable, healthy and fertile with no changes in morbidity. They are also normal in 
terms of gross morphology and anatomy, tissue histology, haematology and clinical 
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chemistry. Double (BACE1 and BACE2) knockout mice despite showing ~60% of neonatal 
mortality, revealed that surviving animals were fertile, and a detailed pathological 
examination do not reveal any abnormality 133.  
The PS proteins might be also involved in gametogenesis. Supporting this idea are 
findings that the C. elegans TM sperm protein spe-4, homologue of PS, is involved in 
trafficking of proteins during sperm differentiation, suggesting a role for PS1 in protein 
trafficking and in sperm morphogenesis 134, but further studies are needed in this regard. 
Additionally, in neonatal mouse testis, it was reported that PS1 was present in both 
spermatogonia and Sertoli cells. This suggests a potential role for this protein through 
Notch signalling in the regulation of the fate of spermatogonial stem cells during the 
process of spermatogenesis 135. PS1 knockout mice 136 and double PS1 and PS2 knockout 
mice 137 die early in embryogenesis, due to disturbances in somitogenesis. This suggests 
that the PS proteins play an important role in directing the development of the axial 
skeleton 136. To overcome this issue, conditional knockouts were developed, in which the 
loss of the gene was limited to the postnatal stage 9. However, to date, it was not reported 
the development of a PS1-null testis mice for the study of this protein in this tissue.  
In contrast, PS2 knockout mice are viable and fertile, and develop only mild 
pulmonary fibrosis and haemorrhage with age 137.  
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2. Objectives 
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APP and Tau have been the target of intense study, since they are related to the 
histopathological hallmarks of AD, a severe neurodegenerative disorder. However, their 
biological functions are still not fully clear, especially in peripheral tissues.  
The general aim of this research was to expand the knowledge of APP and Tau, and 
more specifically to study the expression of these two proteins in mouse and rat testis, 
contributing to a better characterization of spermatogenesis. Thus, the specific objectives 
are to: 
– Determine and characterize the expression of APP and phosphorylated APP in 
testis; 
– Determine and characterize the expression of Tau and phosphorylated Tau in 
testis; 
– Determine if APP and Tau could potentially be involved in spermatogenesis; 
– Determine the profiles for APP in testis with ageing. 
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3. Materials and Methods 
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 Animals  
Male C57BL/6 mice with a range of age between 2 and 15 months, and male Wistar 
Han rats with a range of age between 5 and 29 months were used. All animals were 
anesthetized with pentobarbital (30 mg/kg) via intramuscular injection in the lower right 
abdominal quadrant and transcardialy perfused with 0.9% saline solution before being 
used for tissue collection. After surgical removal of a testicle, the animals were 
transcardialy perfused with 4% paraformaldehyde fixative and the other testicle was 
removed surgically. This procedure was carried out at the University of Minho (Braga, 
Portugal), under the supervising of Professor Doctor João Carlos Sousa. 
All experiments were conducted in accordance with the Portuguese national 
authority for animal experimentation, Direcção Geral de Veterinária (ID: DGV9457). 
Animals were kept and handled in accordance with the guidelines for the care and handling 
of laboratory animals in the Directive 2010/63/EU of the European Parliament and of the 
Council. Efforts were made to minimize the number of animals used and their suffering. 
 
 
 Antibodies 
Antibodies belong to the class of serum proteins known as immunoglobulins (Ig) that 
are present in the blood of immunized animals. There are five major classes of antibodies 
found in the blood of higher vertebrates: IgG, IgA, IgM, IgD, and IgE (listed in order of 
decreasing quantity found in plasma or serum) 138,139. IgG is the most common and a 
frequently used antibody for laboratorial techniques. The IgG molecule is composed of two 
light chains and two heavy chains linked by disulphide bonds and noncovalent interactions 
to form a Y-shaped structure. The terminal regions of each arm vary in a.a. sequence and 
are known as variable domains. This variability in a.a. content provides specificity for a 
particular epitope and enables the antibody to bind specifically to the antigen against which 
it was raised 138. 
Antibodies are the pivotal reagent in many laboratorial techniques. There are two 
types of antibodies: i) the monoclonal antibodies, that are a homogeneous population of 
Ig directed against a single epitope; ii) and the polyclonal antibodies, that are a 
heterogeneous mixture of antibodies directed against various epitopes of the same antigen 
140. Table 6 is a summary of the different antibodies used in this study. 
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Table 6: Summary of the primary antibodies used for detection of the target proteins in the different assays. 
Antibody 
Antibody 
type 
Target Epitope Dilution 
Anti-APP, clone 
22C11 
(Chemicon) 
Mouse 
monoclonal 
a.a. 66-81 of APP (N-terminal), 
recognizing all three isoforms of APP 
(APP695, 751, 770), sAPP (α and β), 
and APLP2 
IHC 1:20 
IB 1:250 
Anti-APP, PAD CT695 
(Invitrogen) 
Rabbit 
polyclonal 
reacts with full-length and N-
terminal truncated forms of APP, C-
terminal membrane-anchored 
fragment of APP that remains after 
α- or β-secretase cleavage (CTF) 
IHC 1:100 
IB 1:500 
Anti-Phospho-APP 
(Thr668) 
(Cell Signaling) 
Rabbit 
polyclonal 
detects different isoforms of 
endogenous APP only when 
phosphorylated at Thr668 (in the 
APP695 isoform) or the 
corresponding position on other 
isoforms 
IHC 1:400 
IB 1:1000 
Anti-Tau, clone Tau-5 
(Chemicon) 
Mouse 
monoclonal 
a.a. 210-241 of Tau, recognizing 
phosphorylated and non-
phosphorylated isoforms of Tau 
(total-Tau) 
IHC 1:200 
IB 1:750 
Anti-Phospho-PHF-
Tau 
(pSer202+Thr205), 
clone AT8 
(Thermo Scientific) 
Mouse 
monoclonal 
recognizes PHF Tau phosphorylation 
at Ser202 and Thr205 
IHC 1:100 
IB 1:500 
Anti-PP1α  
(CBC2C) 141 
Rabbit 
polyclonal 
reacts with PP1α IHC 1:250 
Anti-PP1γ 
(CBC3C) 141 
Rabbit 
polyclonal 
detects both PP1γ isoforms, PP1γ1 
and PP1γ2 
IHC 1:500 
Anti-γ-Tubulin 
(GeneTex) 
Rabbit 
polyclonal 
a.a. 1-184 of γ-Tubulin, detecting γ-
Tubulin 
IHC 1:500 
Anti-β-Tubulin,      
clone 2-28-33 
(Invitrogen) 
Mouse 
monoclonal 
reacts with β-Tubulin IB 1:1000 
Abbreviations: a.a., amino acids; APP, Amyloid Precursor Protein; C-terminal, Carboxy-terminal; CTF, Carboxy-
Terminal Fragment; IB, Immunoblotting; IHC, Immunohistochemistry; N-terminal, amino-terminal; PAD, 
Polyclonal Antibody Designation; PHF, Paired Helical Filament; PP, Serine/Threonine Protein Phosphatase; 
sAPP, soluble Amyloid Precursor Protein; Ser, Serine; Thr, Threonine. 
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 Immunohistochemistry  
IHC is a technique for identifying antigens (cellular or tissue constituents) through 
antigen-antibody interactions. The site of antibody binding can be identified either by 
direct labelling of the antibody (the primary antibody is conjugated directly to the label), or 
by a secondary labelling method. In the latter a labelled secondary antibody directed 
against the immunoglobulin of the animal species in which the primary antibody was raised 
visualizes an unlabelled primary antibody. The secondary labelling method is more 
sensitive than the direct technique, once multiple secondary antibodies may react with 
different antigenic sites on the primary antibody, thus increasing the signal amplification. 
Another advantage is the versatility offered for this technique, once the same labelled 
secondary antibody can be used with a variety of primary antibodies raised from the same 
animal species. The conjugate of a labelled antibody, primary or secondary, may be either 
an enzyme or, more commonly, a fluorochrome 138. 
Ensuring preservation of tissue architecture and cell morphology is a very important 
requirement for all routine histological and cytological research, and is done by adequate 
and appropriate fixation. There are a great variety of fixatives, and the choice will depend 
on the individual laboratory. To achieve consistent demonstration of tissue antigens a quick 
fixation of thin slices of tissue is essential. Delayed or poor fixation may cause loss of 
antigenicity or diffusion of antigens into the surrounding tissue. Following fixation, most 
material is routinely processed to paraffin wax to facilitate section cutting. The chemical 
processes involved in fixation and paraffin processing can mask antigens. Intermolecular 
and intramolecular cross-linkages are formed with certain structural proteins in these 
processes, and are responsible for the masking of the tissue antigens. This adverse effect 
has been thought to be the result of the formation of methylene bridges between reactive 
sites on tissue proteins. These reactive sites include primary amines, amide groups, thiols, 
alcoholic hydroxyl groups, and cyclic aromatic rings. The degree of masking of the antigenic 
sites depends upon the length of time in fixative, fixative concentration, temperature, and 
availability of other nearby proteins able to undergo cross-linkage. Some of the most 
common manual methods for antigen unmasking include: microwave oven irradiation, 
proteolytic enzyme digestion, combined microwave oven irradiation and proteolytic 
enzyme digestion, pressure cooker heating, autoclave heating, water bath heating, and 
steamer heating 138. In the particular case of immunofluorescence, an antigen retrieval 
technique can be used to enhance intensity and reduce autofluorescence 142. 
Another important step is the blocking one. The blocking buffer has as the main 
function to reduce background and unspecific staining. The ideal blocking buffer will bind 
to all potential sites of non-specific interaction (reactive sites). This will improve the 
sensitivity of the assay by improving the signal:noise ratio and eliminating background 
altogether without altering or obscuring the epitope for antibody binding. There are several 
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blocking buffers, once no single protein or mixture of proteins works best for all IHC 
experiments. The blocking buffer choice will depend on the specific antibodies and 
detection system that will be used. The universal blocking buffer has normal serum, protein 
solutions, and a buffer, usually Phosphate Buffered Saline (PBS). Foetal Bovine Serum (FBS) 
is a common blocking reagent, because the serum carries antibodies that bind to reactive 
sites and therefore prevents non-specific binding of the secondary antibodies used in the 
assay. Besides serum, concentrated protein buffers made with gelatine, non-fat dry milk or 
0.1 to 5% w/v Bovine Serum Albumin (BSA) are often used to coat all proteins in the sample, 
working as blocking and stabilizer reagent. This approach basically forces primary 
antibodies to out-compete the blocking protein for binding to cognate ligands while 
reducing non-specific binding. This is based on the principle that antibodies have no greater 
binding affinity for non-specific epitopes than do the buffer proteins. To detect intracellular 
antigens, the blocking buffer is not complete without a penetration enhancer reagent, like 
Triton X-100. This detergent is one of the most popular reagents for increasing the cell 
permeability and so improving antibody penetration, given that it partially dissolves the 
cell membranes. It is recommended, for best results, that the blocking buffer must be made 
fresh prior to use and stored at 4°C 138,143. 
 
Fluorescent IHC (Paraffin-Embedded Tissue) Protocol  
Mouse testes were removed surgically, fixed with 4% paraformaldehyde fixative, 
embedded in paraffin wax and sectioned using a microtome. Cross-sections (4 µm) were 
deparaffinised in xylene, hydrated in graduated ethanol (100% for 10 minutes, 90% and 
80% for 5 minutes, and 70% for 10 minutes) and in running tap water for 10 minutes. Heat-
mediated antigen retrieval was performed using 0.01 M citrate buffer (pH 6.0; pre-
warmed), and a microwave oven on high power (800 W) for 15 minutes. After cooling, 
sections were placed in a dark humid chamber and incubated with blocking buffer, which 
contain 5% w/v BSA, 4% v/v FBS, and 0.1% v/v Triton X-100 in PBS 1x, at room temperature 
for 1 hour. Then they were incubated with primary antibodies diluted in blocking buffer 
(for dilutions of primary antibodies see Table 6) at 4°C overnight, and then washed three 
times with PBS 1x. Immunoreactive elements were visualized with the appropriate 
secondary antibody labelled with fluorophore (anti-mouse, anti-rabbit; diluted 1:500 in 
blocking buffer) (Table 7) by treating at room temperature for 2 hours, and then washed 
three times with PBS 1x. Nuclei were counterstained with Hoechst 33342 (Invitrogen; 
diluted 1:3000) for 5 minutes, and then washed three times with PBS 1x. The slides were 
mounted and coverslipped using a temporary mount of 50% of glycerol.  
The multiple staining IHC, for detection of two or more targets on one section, was 
performed as a simultaneous staining. The only difference from the traditional method 
described above is that the two primary antibodies raised in different host species were 
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applied simultaneously. Therefore, the primary antibodies mixture can be visualized using 
a system based on anti-mouse and anti-rabbit secondary antibodies labelled with different 
fluorochromes (Table 7), allowing the distinction between primary antibodies. This 
simultaneous staining method is less time-consuming and there is no signal loss with the 
washes steps than the sequential method, since primary and secondary antibodies can be 
mixed together in two incubation steps. Though, it requires avoiding all cross-reactivity 144. 
The combination used was APP clone 22C11 with APP CT695 (for dilutions see Table 6).  
Stained images were obtained with an IX81 Motorized Inverted Microscope (Olympus 
Corporation, Hamburg, Germany) with an LCPlanFl 20x/0.40 objective lens, and analysed 
with AnalySIS 3.2 Soft Imaging System GmbH software attached to the IX81. 
The pH of prepared solutions was taken into account, for the correct performance of 
the technique, which had to be adjusted. Negative controls were utilized to assess the 
specificity of the immunostaining. In the negative control the primary antibody and/or 
secondary antibody were replaced by PBS 1x. 
 
Table 7: Summary of the secondary antibodies used for detection of the various primary antibodies used in 
immunohistochemistry. 
Antibody 
Excitation 
maximum (nm) 
Emission 
maximum (nm) 
Observed 
colour 
Alexa Fluor 594 goat 
anti-mouse IgG (H+L) 
(Invitrogen) 
590 617 Red 
Alexa Fluor 594 goat 
anti-rabbit IgG (H+L) 
(Invitrogen) 
590 617 Red 
Alexa Fluor 488 goat 
anti-rabbit IgG (H+L) 
(Invitrogen) 
495 519 Green 
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Figure 12: Schematic representation of the fluorescent immunohistochemistry protocol performed in this 
study, using paraffin-embedded tissue. 
Abbreviation: BSA, Bovine Serum Albumin; EtOH, Ethanol; FBS, Foetal Bovine Serum; PBS, Phosphate Buffered 
Saline. 
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 Western Blot Analysis 
Western blot technique is an analytical method that allows the separation and 
identification of specific proteins from a complex mixture of proteins extracted from cells 
or tissues. This technique uses three steps to accomplish this task: i) a mixture of proteins 
is separated by size (molecular weight), through gel electrophoresis; ii) transfer to a solid 
support (membrane) producing a band for each protein; and iii) marking target protein, by 
incubating the membrane, using a proper primary (specific to the protein of interest) and 
secondary antibody to visualize (immunoblotting). The unbound antibody is washed off 
leaving only the bound antibody to the protein of interest. The bound antibodies are then 
detected by developing the film. As the antibodies only bind to the protein of interest, only 
one band should be visible. The thickness of the band corresponds to the amount of protein 
present; thus doing a standard can indicate the amount of protein present 145. 
After extracting the proteins from the samples, it is important to determine the 
extract's concentration. This allows to ensure that the samples are being compared on an 
equivalent basis. Protein concentration is often measured using the bicinchoninic acid 
(BCA) method, described below. Using the protein concentration allows to measure the 
mass of the protein (50 µg) that is being loaded into each well. After determining the 
appropriate volume of the sample, it is diluted into a loading buffer, which contains glycerol 
that gives density to the samples and so these sink easily into the wells of the gel. A tracking 
dye (bromophenol blue) is also present in the loading buffer allowing to see how far the 
separation has progressed. After being diluted into a loading buffer containing Sodium 
Dodecyl Sulphate (SDS) and a reducing agent (β-mercaptoethanol), the sample is boiled in 
order to denature the higher order structure, while retaining sulphide bridges. Denaturing 
the high structure ensures that the negative charge of a.a. is not neutralized, enabling the 
protein to move in the electric field applied during electrotransfer 145.  
Western blot gel electrophoresis uses two different types of agarose gel: stacking and 
resolving gel. The higher, stacking gel is slightly acidic (pH 6.8) and has a lower acrylamide 
concentration making a non-restrictive porous gel, which separates protein poorly but 
allows them to form thin, sharply defined bands. The lower gel, resolving or separating gel, 
is basic (pH 8.9), and has a higher polyacrylamide content, making the gel's pores narrower. 
This allow that the smaller proteins to travel more easily and rapidly, than the larger 
proteins, causing them to separate by their molecular weight. The gel percentage and size 
depend on the molecular weight of the proteins to be separated. Since proteins when 
loaded on the gel have a negative charge, as they have been denatured by heating, and will 
travel toward the positive electrode when a voltage is applied 145. 
After separating the protein mixture by molecular weight, it is transferred to a solid 
support, a membrane. The transfer is done using an electric field oriented perpendicular to 
the surface of the gel, causing proteins to move out of the gel and onto the membrane. The 
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membrane is placed between the gel surface and the positive electrode in a sandwich, so 
that the negatively charged proteins can migrate from the gel to the membrane. The 
sandwich includes a fibber pad (sponge) at each end, and filter papers to protect the gel 
and the blotting membrane 145.  
 
3.4.1. Tissue Homogenization 
Mouse (n=3) and rat (n=8) testes were removed surgically after the animals were 
transcardialy perfused with 0.9% saline solution, and stored at -80°C until use. Lysis buffer 
(50 mM Tris-HCl (pH 8.0), 120 mM NaCl, 4% w/v 3[(3-Cholamidopropyl)dimethylammonio]-
propanesulfonic acid (CHAPS)) containing protease inhibitors cocktail were added to 
tissues, and then homogenized in a variable speed motor drive homogenizer (750-1000 
rpm; Yellowline OST 20 Digital; IKA Labortechnik) with a pestle tissue grinder. After, the 
homogenized tissues were transferred to a sterile tube and centrifuged at 1000 rcf at 4°C 
for 2 minutes, to separate the proteins from the non-homogenized tissue, like the thick 
fibrous connective tissue capsule (the tunica albuginea) that covered the testes. The 
supernatant was transferred to a new sterile tube and then each sample was sonicated 
twice on ice for 10 seconds (0.5 cycle; 60% amplitude; Sonicator U200S control; IKA 
Labortechnik). Each sample was made up to 1% SDS and boiled at 90°C for 10 minutes, and 
stored at -20°C until use. 
Lysis buffer containing protease inhibitors was used considering that allows an 
efficient tissue lysis and protein solubilisation, while prevents protein degradation and 
interference with the protein´s immunoreactivity and biological activity. 
 
3.4.2. Total Protein Concentration Determination 
Total protein concentration of the tissue lysates was determined using the BCA 
Protein Assay (Thermo Scientific Pierce). This kit is a fast (two-component), high-precision, 
detergent-compatible assay reagent set to measure total protein concentration compared 
to protein standards (Table 8). The BCA Protein Assay combines the reduction of Cu2+ to 
Cu1+ by protein in an alkaline environment with the highly sensitive and selective 
colorimetric detection of the cuprous cation (Cu1+) by BCA. The first step of the colour 
development reaction is the biuret reaction, where peptides containing three or more a.a. 
residues form a coloured chelate complex (light blue) with cupric ions (Cu2+) in an alkaline 
medium containing sodium potassium tartrate. In the second reaction occurs the chelation 
of two molecules of BCA with one reduced cuprous cation, which was formed in step one, 
resulting in the formation of the intense purple-coloured reaction product. The water-
soluble BCA/copper complex displays a strong linear absorbance at 562 nm with increasing 
protein concentrations over a working range of 20 μg/mL to 2000 μg/mL. The BCA reagent 
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is approximately 100 times more sensitive than the light blue colour of the first reaction 
146. 
The reaction that leads to BCA colour development is strongly influenced by four a.a. 
residues in the a.a. sequence of the protein, which are cysteine, cystine, tyrosine, and 
tryptophan. Though, the universal peptide backbone also contributes to colour formation, 
helping to minimize variability caused by protein compositional differences 146. 
 
Table 8: Protein standards used in BCA Protein Assay method. 
Protein 
Standard 
BSA 2 mg/mL 
(µL) 
SDS 1% 
(µL) 
Protein Mass 
(µg) 
Protein Concentration 
(µg/µL) 
P0 0 25 0 0.00 
P1 1 24 2 0.08 
P2 2 23 4 0.16 
P3 5 20 10 0.40 
P4 10 15 20 0.80 
P5 20 5 40 1.60 
Abbreviations: BSA, Bovine Serum Albumin; SDS, Sodium Dodecyl Sulphate. 
 
The quantitative analyses of total protein concentration were carried out using four 
dilutions of the samples (5 μL, 2.5 μL, 1 μL and 0.5 μL, with final volumes of 25 μL that were 
adjusted with SDS 1%). After preparation of protein standards and samples in a 96 well 
plate, they were incubated at 37°C for 30 minutes with 200 µL of working reagent 
(composed of 50 parts of reagent A to 1 part of the reagent B). Immediately after incubation 
the absorbance was measured at 562 nm using the microplate reader Infinite M200 (Tecan, 
Männedorf, Switzerland) and analysed with Tecan i-control 1.9 software attached to the 
Infinite M200. The standard curve was prepared by plotting the absorbance value for each 
BSA standard against its concentration (Table 8). The total protein concentration of each 
sample was determined using the standard curve. Duplicates of protein standards and 
samples were always prepared. 
 
3.4.3. Gradient SDS Polyacrylamide Gel Electrophoresis 
The 5-20% gradient SDS polyacrylamide gel were prepared and allowed to polymerize 
at room temperature for 45 minutes. This resolving gel has a linear progression of 
acrylamide concentrations (5 to 20%) from top to bottom, resulting in a wider separation 
range. Next, the stacking gel solution was prepared and loaded on the top of gradient gel. 
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A comb was inserted and the gel was left to polymerize for 30 minutes at room 
temperature. Prior to loading the samples on the wells of the stacking gel, ¼ volume of 
loading buffer 4x (250 mM Tris (pH 6.8), 0.01% w/v bromophenol blue, 2% v/v β-
mercaptoethanol, 8% w/v SDS, and 40% v/v glycerol in sterile deionized H2O) was added to 
the sonicated samples. After boiling at 90°C for 10 minutes and spinned down, the mass-
normalized samples were subjected to electrophoresis on a 7.5 and 5-20% gradient SDS 
polyacrylamide gel in a Hoefer electrophoresis system at 90 mA for approximately 3 hours.  
Precision Plus Protein™ Dual Colour Standards (Bio Rad) was used as molecular 
weight marker, and were loaded and resolved side-by-side with the samples. 
 
3.4.4. Immunoblotting 
After the samples were electrophoresed, proteins were transferred from gel to a 
nitrocellulose membrane (0.2 µm pore size; Whatman®) at 200 mA for approximately 18 
hours. Nitrocellulose membrane was used for its high affinity for protein, its retention 
abilities, highly versatile (several staining options), and low background.  
The membranes were initially hydrated with Tris Buffered Saline (TBS) 1x for 5 
minutes at room temperature. Then were incubated with blocking buffer (5% w/v BSA in 
Tris Buffered Saline-Tween (TBS-T) 1x) at room temperature for 4 hours with gentle 
agitation and at 4°C overnight. This is a very important step of western blotting, as it 
prevents antibodies from binding to the membrane non-specifically, reducing the 
background. After blocking, the proteins of interest were detected incubating the 
membranes with specific antibodies at room temperature for 4 hours with gentle rocking 
and at 4°C overnight. The antibodies used were: Anti-APP, clone 22C11 (Chemicon); Anti-
APP, PAD CT695 (Invitrogen); Anti-Phospho-APP (Thr668) (Cell Signaling); Anti-Tau, clone 
Tau-5 (Chemicon); Anti-Phospho-PHF-Tau (pSer202+Thr205), clone AT8 (Thermo 
Scientific); and Anti-β-Tubulin, clone 2-28-33 (Invitrogen). The antibodies were diluted in 
5% w/v BSA in TBS-T 1x, according to the manufacturer’s instructions (for dilutions of 
primary antibodies see Table 6). The membranes were washed with TBS-T 1x, 3 times, 10 
minutes each time. Washing is very important as it minimizes background and removes 
unbound antibody. Bound primary antibodies were detected by an appropriate horseradish 
peroxidase (HRP) conjugated second antibody (Amersham™ ECL™ Anti-mouse IgG, 
Horseradish Peroxidase-Linked Species-Specific Whole Antibody (from sheep), and 
Amersham™ ECL™ Anti-rabbit IgG, Horseradish Peroxidase-Linked Species-Specific Whole 
Antibody (from donkey); GE Healthcare Life Sciences; diluted 1:5000) after 2 hours at room 
temperature incubation with gentle agitation. After washing with TBS-T 1x, 3 times, 10 
minutes each time, the membranes were incubated with an enhanced chemiluminescence 
(ECL) Luminata Crescendo Western HRP substrate (Merck Millipore) for 2-5 minutes, or 
with a homemade ECL detection reagent (100 (0.1 mM 3-aminophthalhydrazide (luminol); 
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2 mM 4-iodophenol; 50 mM Tris (pH 9.35)) : 1 (hydrogen peroxide)) for 1 minute, both at 
room temperature. The signal that is produced corresponds to the position of the target 
protein. This signal was captured on an X-ray film (Amersham Hyperfilm ECL; GE Healthcare 
Life Sciences), which was developed and fixed in a dark room with the appropriate 
solutions. The X-ray films were scanned on a GS-800™ Calibrated Densitometer (Bio-Rad 
Laboratories, Amadora, Portugal) and analysed with the Image Lab™ Software version 5.1 
(Bio-Rad Laboratories, Amadora, Portugal). 
Chemiluminescence is the most commonly used enzymatic detection system. This 
method is based on antibodies conjugated to HRP that catalyse the oxidation of luminol in 
presence of luminol peroxide detection reagent, in a multi-step reaction. The result is the 
emission of low intensity light at 428 nm 147. 
The membranes were incubated with stripping buffer (62.5 mM Tris base, 2% w/v 
SDS, and 0.7% v/v β-mercaptoethanol in deionized H2O) at 50°C for 30 minutes with gentle 
rocking, to stripping for re-probing the membranes. The membranes were washed with 
TBS-T 1x, 5 times, 15 minutes each time (until the β-mercaptoethanol was totally removed). 
Then, the membranes were washed 2 times with deionized H2O, and were allowed to dry 
until the next re-probing treatment. 
The proteins quantifications were normalized against the amount of β-tubulin (clone 
2-28-33; 1:1000; Invitrogen) to correct for loading. 
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Figure 13: Diagram of the western blot protocol performed in this study, using mouse and rat testes. 
Abbreviations: BCA, Bicinchoninic Acid; SDS, Sodium Dodecyl Sulphate. 
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Figure 14: Schematic representation of the immunoblotting protocol performed in this study. 
Abbreviations: BSA, Bovine Serum Albumin; ECL, Enhanced Chemiluminescence; HRP, horseradish 
peroxidase; TBS, Tris Buffered Saline; TBS-T, Tris Buffered Saline-Tween. 
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4. Results – Setting up fluorescent 
immunohistochemistry 
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 Abstract 
Upon initiating the experiments designed it became apparent that the tissues had 
autofluorescence, which was interfering with fluorescent IHC performed. Thus, the initial 
objective was to found in the available literature and test the best possible treatment in 
order to decrease autofluorescence. The overall aim was to establish the conditions for the 
subsequent experiments. Antigen retrieval pre-treatment with citrate buffer and an 
indirect immunofluorescent staining method was the strategy implemented to reduce the 
autofluorescence problem. 
 
 Results – Detecting Autofluorescence 
Autofluorescence was one of the problems in the course of this study. To better 
evaluate the tissue autofluorescence, fluorescent IHC (on paraffin-embedded tissue) 
protocol was performed without primary and secondary antibodies incubation. Also, no 
antigen retrieval pre-treatment was performed, given the fact that this pre-treatment can 
reduce autofluorescence 142. The next figures show testis sections from 2-month-old mouse 
(Figure 15) and 29-month-old rat (Figure 16). Interstitial cells (Figures 15 and 16), as well as 
myoid cells and Sertoli cells (Figure 16) exhibited elevated levels of autofluorescence. In 
testis of younger animals, mainly the interstitial cells exhibited fluorescence. In older 
animals, autofluorescence was observed in myoid cells (peritubular layer of the 
seminiferous tubules) and in Sertoli cells. Thus, testis autofluorescence appears to be age-
related, once it was observed an increase in the autofluorescence levels with ageing, as 
well as an increase in the cell types affected. 
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Figure 15: Autofluorescence of testis from 2-month-old mouse. 
No antigen retrieval pre-treatment and no primary and secondary antibodies incubations were performed in 
this section. A) Blue signals represent nuclear DNA counterstained with Hoechst 33342 (diluted 1:3000). B) 
and C) Green and red signals represent the tissue autofluorescence capture with GFP and TRITC, respectively. 
D) Merged image. Bar = 100 µm. Magnification 200x. 
 
 
Figure 16: Autofluorescence of testis from 29-month-old rat. 
No antigen retrieval pre-treatment and no primary and secondary antibodies incubations were performed in 
this section. A) Blue signals represent nuclear DNA counterstained with Hoechst 33342 (diluted 1:3000). B) 
and C) Green and red signals represent the tissue autofluorescence capture with GFP and TRITC, respectively. 
D) Merged image. Bar = 100 µm. Magnification 200x. 
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These results were consistent with the findings of Miquel and colleagues (1978). They 
investigated by spectrophotofluorometric and electron microscopic techniques the 
lipofuscin accumulation in the testis of C57BL/6J mice ranging in age from 4 to 39 month. 
It was reported that mice testes contained fluorescent substances, which increased linearly 
until about 24 months. From that age on, no further increase were observed. Through 
electron microscopy, they showed that spermatogonia were completely free of lipofuscin. 
In striking contrast, both Sertoli and interstitial cells of Leydig, in old animals, had 
accumulated very large amounts of pigment. In the Sertoli cells, a process of mitochondrial 
vacuolation and densification was apparently linked with the genesis of lipofuscin. On the 
other hand, in the interstitial cells, densification of lipid droplets played a role in the 
formation of most pigment granules 148. 
Ceroid/lipofuscin-type pigments are the responsible for cell and tissue 
autofluorescence. These pigments are classified and defined as follows:  
i. Lipofuscin is an intracellular, age-related, fluorescent, cytoplasmic, non-degradable 
granular pigment. It is mostly present in secondary lysosomes of post-mitotic cells, such as 
neurons, cardiac myocytes, and retinal pigment epithelial cells, which forms due to iron-
catalysed oxidation/polymerization of protein and lipid residues 149;  
ii. Ceroid is a group of biopigments, also with an intralysosomal location, which are 
quickly produced as a result of several pathologies and experimental conditions, such as x-
irradiation, E-vitamin deficiency, starvation, and intoxication. Ceroid is probably similar to 
lipofuscin and may share the same mechanisms of formation, but it does not accumulate 
with age. It may be present in a variety of cells, like in the kidney, thymus, pancreas, testis, 
prostate, seminal vesicles, uterus, and adrenal gland 149,150.  
The emission wavelength of the autofluorescent substance ranged from 425 to 700 
nm, a range sufficiently broad that could potentially interfere with fluorescence techniques 
151.  
 
 Results – Reducing the Autofluorescence 
Different strategies have been advanced to combat the inherent diffuse 
autofluorescence problem, including extraction of the autofluorescent constituents, 
chemical modification of the fluorochrome, photobleaching methods, and “blocking” the 
autofluorescent structures. To date, none of these approaches has fully succeeded, in part 
because effectiveness of the “blocking steps” varies by tissue type and method of 
processing 142. Viegas et al. (2007) concluded that a combination of short-duration, high-
intensity ultraviolet irradiation (2 hours at 30 W) and Sudan Black B was the best protocol 
to reduce autofluorescence regardless of the extent of vascularity and level of lipofuscin 
content 152. A different approach was advocated by Robertson et al. (2008) that reported a 
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combined approach to multiple immunofluorescent labeling of formalin-fixed paraffin-
embedded tissue, using antigen retrieval pre-treatment, an indirect immunofluorescent 
staining method, and confocal laser scanning microscopy to circumvent autofluorescence 
153. Yang and Honaramooz (2012) reported that the intrinsic fluorescence was completely 
masked after treatment with Sudan Black B for 10-15 minutes of the Piglet testis tissue 
sections or for 8 minutes of the testis cells 151.  
In this study, antigen retrieval pre-treatment and an indirect immunofluorescent 
staining method was the strategy implemented to combat the autofluorescence problem. 
This approach wasn’t fully effective at completely eliminating the autofluorescence 
problem. Nonetheless there was a substantial reduction in autofluorescence in the 
seminiferous tubules, but not in the interstitial space (Figure 17 and 18). Thus, in IHC 
analysis of the different antibodies tested in this study, was only considered the staining 
within the seminiferous tubules. 
 
 
Figure 17: Autofluorescence of testis from 2-month-old mouse, after antigen retrieval pre-treatment. 
No primary antibody incubation was performed in this section. Spermatocytes during meiotic division 
(arrows) are present. A) Blue signals represent nuclear DNA counterstained with Hoechst 33342 (diluted 
1:3000). B) Red signals represent the tissue autofluorescence capture with TRITC. C) Merged image. Bar = 100 
µm. Magnification 200x. 
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Figure 18: Autofluorescence of testis from 26-month-old rat, after antigen retrieval pre-treatment. 
No primary antibodies incubation was performed in this section. A) Blue signals represent nuclear DNA 
counterstained with Hoechst 33342 (diluted 1:3000). B) Red signals represent the tissue autofluorescence 
capture with TRITC. C) Merged image. Bar = 100 µm. Magnification 200x. 
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5. Results – Tau protein, PP1α and PP1γ  
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 Abstract 
Having established ideal conditions to reduce tissue inherent autofluorescence, we 
work on to test proteins relevant to Tau phosphorylation in testis. Thus, fluorescent IHC 
was carried out for Tau, phosphorylated Tau, serine/threonine protein phosphatase (PP) 
1α, and PP1γ. The seminiferous epithelium of the mammalian testis has a variety of MT 
networks: an ordered array in Sertoli cells, the manchette, axonemal MTs and in mitotic 
and meiotic spindles. These abundant MT networks are reflected by a diversity of MAPs. 
Thus, the testis are an abundant source for studies of MTs and MAPs 73. 
The overall aim was to analyse the Tau protein expression and its dynamics of 
phosphorylation patterns during spermatogenesis.  
Results showed that all cells of spermatogenic lineage express Tau protein. 
Phosphorylated Tau (Ser202 and Thr205) is localized all over spermatogonia, 
spermatocytes and early (round) spermatids. PP1α and PP1γ are expressed throughout 
spermatogenesis. 
 
 Results – Tau 
IHC using the monoclonal anti-Tau, clone Tau-5 antibody detected the localization of 
total-Tau protein during spermatogenesis. Tau was detected throughout spermatogenesis, 
all over the cells in a diffuse way (Figures 19). 
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Figure 19: Tau protein expression in testis from 6-month-old mouse. 
A) Blue signals represent nuclear DNA counterstained with Hoechst 33342 (diluted 1:3000). B) Red signals 
represent immunostaining with anti-Tau-5 (diluted 1:200). C) Merged image. Bar = 100 µm. Magnification 
200x. 
 
 
 Results – Tau Phosphorylation 
IHC using the monoclonal anti-phospho-PHF-Tau (Ser202+Thr205), clone AT8 
antibody detected Tau protein only when phosphorylated (simultaneously) at Ser202 and 
Thr205 during spermatogenesis. AT8 was localized all over spermatogonia, spermatocytes 
and early (round) spermatids (Figures 20 and 21) in a diffuse way. We observed a decrease 
in the AT8 expression pattern between the ages of 3-month-old (Figure 20) and 15-month-
old (Figure 21). It was necessary to increase the exposure time from 100 milliseconds to 
500 milliseconds, respectively. 
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Figure 20: Phosphorylated Tau (Ser202 and Thr205) expression in testis from 3-month-old mouse. 
This section and the section in Figure 27 are serial sections each other. A) Blue signals represent nuclear DNA 
counterstained with Hoechst 33342 (diluted 1:3000). B) Red signals represent immunostaining with anti-AT8 
(diluted 1:100). C) Merged image. Bar = 100 µm. Magnification 200x. 
 
 
Figure 21: Phosphorylated Tau (Ser202 and Thr205) expression in testis from 15-month-old mouse. 
This section and the section in Figure 28 are serial sections each other. Spermatocytes during meiotic division 
(arrows) are present. A) Blue signals represent nuclear DNA counterstained with Hoechst 33342 (diluted 
1:3000). B) Red signals represent immunostaining with anti-AT8 (diluted 1:100). C) Merged image. Bar = 100 
µm. Magnification 200x. 
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 Results – PP1α 
IHC using the polyclonal anti-PP1α antibody detected total Serine/Threonine Protein 
Phosphatase PP1α during spermatogenesis. All cells of spermatogenic lineage exhibited a 
diffuse cytoplasmic stain with this antibody (Figure 22). PP1α was localized all over cells 
including around the nucleus, and presented higher intensity in spermatogonia (Figure 
22B). 
 
Figure 22: PP1α expression in testis from 2-month-old mouse. 
This section and the section in Figure 23, 24 and 25 are serial sections each other. A) Blue signals represent 
nuclear DNA counterstained with Hoechst 33342 (diluted 1:3000). B) Red signals represent immunostaining 
with anti-PP1α (diluted 1:250). C) Merged image. Bar = 100 µm. Magnification 200x. 
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 Results – PP1γ 
IHC using the polyclonal anti-PP1γ antibody detected both Serine/Threonine Protein 
Phosphatase PP1γ isoforms (PP1γ1 and PP1γ2) during spermatogenesis. All cells of 
spermatogenic lineage presented a diffuse cytoplasmic stain with this antibody (Figure 23). 
PP1γ was localized all over cells including around the nucleus, and stained more intensely 
the spermatogonia and the late (elongated) spermatids heads and midpieces (Figure 23B). 
 
 
Figure 23: PP1γ expression in testis from 2-month-old mouse. 
This section and the section in Figure 22, 24 and 25 are serial sections each other. A) Blue signals represent 
nuclear DNA counterstained with Hoechst 33342 (diluted 1:3000). B) Red signals represent immunostaining 
with anti-PP1γ (diluted 1:500). C) Merged image. Bar = 100 µm. Magnification 200x. 
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 Discussion 
Tau promotes assembly of tubulin in vitro 86 and stabilizes MTs against 
depolymerization in vivo 154,155. Grundke-Iqbal et al. (1986) described that an increase in 
Tau protein phosphorylation reduces its affinity for MTs, which results in neuronal 
cytoskeleton destabilization 87. In opposition, the function of Tau protein and its 
phosphorylation in the testis has only recently begun to be characterized 73.  
In this immunohistochemichal analysis we studied Tau’s expression and its 
phosphorylation patterns in the testis. Total-Tau expression, detected by anti-Tau-5, was 
constantly observed from spermatogonia to late (elongated) spermatids (Figure 19). 
Although, anti-AT8, which detect phosphorylated Tau at Ser202 and Thr205, was localized 
from spermatogonia to early (round) spermatids (Figure 20 and 21). These findings are in 
agreement with H. Inoue et al. (2014) findings 73. They used a battery of antibodies to study 
Tau phosphorylation patterns in the C57BL/6 mice testis at 12 weeks of age. 
Phosphorylated Tau (P-TauS199,S202, AT8, AT100 and AT270) was especially localized in 
spermatocytes during meiosis in their study, as well as in ours (arrows in Figure 21). They 
also reported that the expression of acetylated tubulin was inversely weakened during the 
same stage. This, according to the authors, suggests that Tau phosphorylation is specific 
during meiosis. In addition, Tau protein might be phosphorylated at AD-specific sites in 
meiosis. Thus, Tau phosphorylation and MT deacetylation may contribute to 
spermatogenesis, particularly in meiosis 73. 
In this study, we observed a decrease in AT8 expression pattern between the ages of 
3-month-old (Figure 20) and 15-month-old (Figure 21), in a way that was necessary to 
increase the exposure time from 100 milliseconds to 500 milliseconds, respectively. In 
order to test this hypothesis, we used western blot analysis to confirm the decrease of Tau 
and phosphorylated Tau expression with age. Unfortunately, despite our best efforts, we 
did not detect any signal with this approach using anti-Tau-5 and anti-AT8. After carefully 
examination of all possible explanations, we concluded that either the concentration of the 
primary antibody was not appropriate, or the antigen was present in low concentration 
145,147. Thus, as future work, we should attempt another western blot analysis, starting to 
increase primary antibody and/or the antigen concentration. If this new attempt does not 
succeed, we should try other techniques, such as immunoprecipitation. 
In the adult rat brain, alternative splicing of the primary transcript of Tau generates 
six isoforms with an apparent molecular weight between 48 and 67 kDa. Still, Gu et al. 
(1996) suggested a testis-specific isoform when they reported that Tau protein was 
detected in two major bands in rat testis at 34 and 37 kDa after alkaline phosphatase 
treatment 66. More recently, it was reported that this protein was detected in some bands 
with apparent molecular weight between 37 and 40 kDa in the mouse testis. Additionally, 
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it was confirmed that Tau isoform-D (identified as P10637-5 in uniprot), of 38.961 kDa, is 
the isoform expressed in mouse testis 73.  
PP1 isoforms belong to the family of serine/threonine protein phosphatases, which 
is involved in Tau dephosphorylation 88, as previously mentioned. The role of PP1 has been 
implicated in various eukaryotic processes including metabolism, cell cycle regulation, 
apoptosis, etc. In mammals, three genes, Ppp1ca, Ppp1cb, and Ppp1cc, encode four PP1 
isoforms: PP1α, PP1β, PP1γ1 and PP1γ2. Ppp1cc gene alternative splicing generates the 
isoforms PP1γ1 and PP1γ2. All four PP1 isoforms are virtually identical (approximately 90% 
identity) except at their extreme C-terminal. Even though PP1γ1, PP1α and PP1β are 
ubiquitous, PP1γ2 is mainly restricted to adult testis 156,157. Ppp1cc gene null mutation, 
which eliminates both splice variants, results in male infertility due to disruptions in 
spermatogenesis 158,159. Females appear normal suggesting that the PP1α and PP1β can 
substitute for the PP1γ isoforms in all tissues except testis 157–159. Curiously, loss of PP1α 
appears to have no apparent phenotype 157. 
Both PP1α (Figure 22) and PP1γ (Figure 23) were detected throughout 
spermatogenesis. Although our PP1γ findings are in agreement with that Chakrabarti et al. 
(2007) described, the PP1α are not 159. In adult mice testis, PP1γ2 was described to be 
localized in the cytoplasm of secondary spermatocytes, round spermatids, and elongated 
spermatids, as well as in testicular and epididymal spermatozoa. However, its expression 
was weak in spermatogonia, pachytene spermatocytes, and interstitial cells. Additionally, 
PP1γ1 expression was observed in interstitial cells, whereas much weaker expression was 
observed in all stages of spermatogenesis, in both the cytoplasm and nuclei of all cells. 
PP1α expression was reported in the cytoplasm of interstitial cells, peritubular cells, 
spermatogonia, and pachytene spermatocytes in adult mice testis 159.   
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6. Results – APP and its phosphorylation  
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6.1. Abstract  
Work from our group has previously identified that APP is expressed in sperm. 
Therefore we work on to address if APP is also expressed in testis. Further, given the 
specific relevance of protein phosphorylation in signalling cascades, we also included the 
study of APP phosphorylated on Thr668. Thus, fluorescent IHC was carried out for APP, 
phosphorylated APP (Thr668), and γ-Tubulin.  
The overall aim was to analyse APP expression and its dynamics of phosphorylation 
patterns during spermatogenesis. 
Results showed that APP is expressed throughout spermatogenesis. Surprisingly, 
results were dramatic in its phosphorylation pattern.  
 
6.2. Results – APP 
IHC using anti-APP 22C11 and anti-APP CT695 antibodies detected total-APP during 
spermatogenesis. The monoclonal antibody anti-APP 22C11 recognizes the N-terminal 
epitope of APP and APLP2, and the polyclonal antibody anti-CT is specific for APP and reacts 
with the intracellular domain of all transmembrane APP isoforms. All cells of spermatogenic 
lineage and Sertoli cells displayed a diffuse cytoplasmic stain with APP 22C11 (Figure 24) 
and APP CT695 (Figure 25). APP 22C11 was localized all over cells except around the 
nucleus, and stained more intensely the spermatocytes (Figure 24B). In contrast, APP 
CT695 was localized all over cells including around the nucleus, and stained more intensely 
the spermatogonia (Figure 25B). 
 
 72 
 
Figure 24: APP expression in testis from 2-month-old mouse. 
This section and the section in Figure 22, 23 and 25 are serial sections each other. A) Blue signals represent 
nuclear DNA counterstained with Hoechst 33342 (diluted 1:3000). B) Red signals represent total-APP and 
APLP2 immunostained with APP 22C11 (diluted 1:20). C) Merged image. Bar = 100 µm. Magnification 200x. 
 
 
Figure 25: APP expression in testis from 2-month-old mouse. 
This section and the section in Figure 22, 23 and 24 are serial sections each other. A) Blue signals represent 
nuclear DNA counterstained with Hoechst 33342 (diluted 1:3000). B) Red signals represent total-APP and C-
Terminal Fragment immunostained with APP CT695 (diluted 1:100). C) Merged image. Bar = 100 µm. 
Magnification 200x. 
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Given that both anti-APP 22C11 and anti-APP CT695 antibodies detect not only APP, 
but also other proteins (APLP2) and fragments (sAPPα and β, and CTFs), a double staining 
IHC using these two antibodies was performed. This was performed to localize the full-
length form of APP during spermatogenesis. All cells of spermatogenic lineage and Sertoli 
cells shown a diffuse cytoplasmic stain for both APP CT695 (Figure 26B) and APP 22C11 
(Figure 26C). 
 
 
Figure 26: APP expression in testis from 6-month-old mouse. 
A) Blue signals represent nuclear DNA counterstained with Hoechst 33342 (diluted 1:3000). B) Green signals 
represent total-APP and C-Terminal Fragment immunostained with APP CT695 (diluted 1:100). C) Red signals 
represent total-APP and APLP2 immunostained with APP 22C11 (diluted 1:20). D) Merged image. Bar = 100 
µm. Magnification 200x. 
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6.3. Results – APP Phosphorylation  
IHC using the polyclonal anti-phospho-APP (Thr668) antibody detected different 
isoforms of endogenous APP only when phosphorylated at Thr668 (in the APP695 isoform) 
during spermatogenesis. All cells of spermatogenic lineage and Sertoli cells showed a weak 
diffuse cytoplasmic stain with this antibody. An intense focal stain was observed in what 
appears to be the spermatocyte nuclei, under the form of a condensate spot (Figures 27 
and 28). Curiously, spermatocytes during meiosis intensely stained with this antibody all 
over the cell (arrows in Figure 27 and 28). There seem to be no major differences in the 
expression pattern between the ages of 3-month-old (Figure 27) and 15-month-old (Figure 
28). 
 
 
Figure 27: Phosphorylated APP (Thr668) expression in testis from 3-month-old mouse. 
This section and the section in Figure 20 are serial sections each other. Spermatocytes during meiotic division 
(arrows) are present. A) Blue signals represent nuclear DNA counterstained with Hoechst 33342 (diluted 
1:3000). B) Red signals represent immunostaining with anti-phospho-APP (Thr668) (diluted 1:400). C) Merged 
image. Bar = 100 µm. Magnification 200x. 
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Figure 28: Phosphorylated APP (Thr668) expression in testis from 15-month-old mouse. 
This section and the section in Figure 21 are serial sections each other. Spermatocytes during meiotic division 
(arrows) are present. A) Blue signals represent nuclear DNA counterstained with Hoechst 33342 (diluted 
1:3000). B) Red signals represent immunostaining with anti-phospho-APP (Thr668) (diluted 1:400). C) Merged 
image. Bar = 100 µm. Magnification 200x. 
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6.4. Results – γ-Tubulin 
IHC using the polyclonal anti-γ-Tubulin antibody detected total γ-Tubulin protein 
during spermatogenesis. At first glance, this antibody seems to be staining throughout the 
cytoplasm of all spermatogenic cells. However, after a closer observation, all cells of 
spermatogenic lineage seem to display a focal cytoplasmic stain, the centrosome (a pair of 
centrioles) (Figure 29).  
 
 
Figure 29: γ-Tubulin expression in testis from 26-month-old rat. 
Spermatocytes during meiotic division (arrows) are present. A) Blue signals represent nuclear DNA 
counterstained with Hoechst 33342 (diluted 1:3000). B) Red signals represent immunostaining with anti-γ-
Tubulin (diluted 1:500). C) Merged image. Bar = 100 µm. Magnification 200x. 
  
 77 
6.5. Results – APP Western Blot Analysis 
In mice testis at 2 and 6 months of age, the anti-APP clone 22C11 antibody, which 
recognizes the N-terminal epitope of APP and APLP2, detected two major bands with 
apparent molecular mass of 107 kDa and 104 kDa, and two minor bands of 54 kDa and 42 
kDa (Figure 30 – Mouse). In rats testis at 5, 26 and 29 months of age, the same antibody 
detected one major band with apparent molecular mass of 110 kDa, and three minor bands 
of 74 kDa, 54 kDa and 43 kDa (Figure 30 – Rat).  
Equal amounts (50 µg) of protein were loaded, and β-tubulin (50 kDa) was used as 
loading control. 
Figure 31 is the graphic representation of the relative protein expression of APP 
(APP/β-Tubulin) in testes from mice and rats, based on the quantification of immunoblot 
in Figure 30. There is a tendency to decrease in APP expression between the ages of 2-
month-old and 6-month-old (Figure 30 and 31 – Mouse). 
 
 
Figure 30: APP expression through western blot analysis of testes from 2-month-old (n = 2) and 6-month-old 
(n = 1) mice, and of testes from 5-month-old (n = 2), 26-month-old (n = 3) and 29-month-old (n = 3) rats. 
APP was detected by anti-APP clone 22C11 (diluted 1:250). In mice this antibody detected two major bands 
with molecular mass of 107 kDa and 104 kDa, and two minor bands with molecular mass of 54 kDa and 42 
kDa. In rats this antibody detected one major band with molecular mass of 110 kDa, and three minor bands 
with molecular mass of 74 kDa, 54 kDa and 43 kDa. β-Tubulin (diluted 1:1000) was used as a loading control. 
 
Using the anti-APP CT695 and anti-phospho-APP (Thr668), results show non-specific 
binding. 
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Figure 31: Relative protein expression of APP in testes from 2-month-old (n = 2) and 6-month-old (n = 1) mice 
(on the left), and in testes from 5-month-old (n = 2), 26-month-old (n = 3) and 29-month-old (n = 3) rats (on 
the right), based on the quantification of immunoblot in Figure 30. Data presented as mean ± standard error 
of the mean. β-Tubulin was used as a loading control. 
 79 
6.6. Discussion  
In human testis, APP is described to be a 184 Fragments Per Kilobase of transcript per 
Million fragments mapped (FPKM) in RNA sequencing expression analysis, and as a protein 
is localized in cells in seminiferous ducts at low levels 160. Mice and rats were used as models 
in this study, once the homology of APP sequence between these two animals and human 
is approximately 97% for the three major APP isoforms 161. 
IHC was performed to investigate the localization of total-APP and its 
phosphorylation patterns in testis. This technique indicated not only APP expression but 
also its phosphorylation patterns in mouse testis. APP expression, detected by anti-APP 
22C11 and anti-APP CT695 antibodies, was constantly observed from spermatogonia to late 
(elongated) spermatids (Figures 24-26), and in the non-proliferating and supporting Sertoli 
cells. This finding is in agreement with studies demonstrating that the APP gene is 
expressed in the two cell types that compose the epithelium in the seminiferous tubules. 
Shoji et al. (1990) have described the presence of APP by immunocytochemistry only during 
sperm formation in the acrosome and the growing tail of spermatids 122. Beer et al. (1995) 
reported that APP is highly expressed in soma and processes of Sertoli cells, and at low 
levels in germ cells in the testes of young adult Wistar rats 123. 
APP 22C11 was localized all over cells except around the nucleus (Figure 24B), while 
APP CT695 was localized all over cells including around the nucleus (Figure 25B). This 
suggests that CTFs, probably AICD, are in nucleus, and is in agreement with findings that 
described that this fragment is involved in nuclear signalling, as a transcription factor 162. 
Evidence indicates that only the amyloidogenic pathway generates AICD capable of nuclear 
signalling, due to the subcellular compartmentalization of APP processing 162. 
Thr668 is a major phosphorylation site within APP that can be phosphorylated by a 
number of kinases 163. CDK5 40 and glycogen synthase kinase (GSK) 3β 41 phosphorylate APP 
at Thr668 in post-mitotic neurons, whereas CDK1 phosphorylate APP in dividing cells 33. 
The c-Jun N-terminal kinase (JNK) 1 and JNK2 also phosphorylate APP at Thr668, after a 
cellular stress signal 42, while JNK3 phosphorylates APP during neuronal differentiation 39. 
The phosphorylation of APP at Thr668 results in a significant conformational change that 
may affect interactions with binding partners and consequently impact its subcellular 
localization and metabolism 164. Phosphorylation at this residue is a normal process 
associated with neurite extension, anterograde transport of vesicular cargo into neurites, 
and in signalling to the nucleus 39,165–168. A recent study has shown that non-phosphorylated 
forms (at Thr668) of C-terminal APP fragments are associated with lipid raft-like 
microdomains where the γ-secretase complex (amyloidogenic) resides, whereas Thr668-
phosphorylated C-terminal fragments reside predominantly in cytoplasmic fractions 169. 
Hence phosphorylation regulates the localization of APP and thus affects its processing by 
γ-secretase 169.  
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In contrast with total-APP localization, anti-phospho-APP (Thr668) antibody was 
especially localized in what appears to be the spermatocyte nuclei (Figures 27 and 28), in 
the present study. We suspect that this staining in the nuclei represent phosphorylated 
AICD (at Thr668). Supporting this idea are the findings reported to Chang et al. (2006), 
which showed that the phosphorylation of AICD at Thr668 is required for its binding to Fe65 
and its translocation into the nucleus. Additionally, phosphorylation of AICD at Thr668 
induce GSK-3β expression, which leads to increased Tau phosphorylation at the Ser202 and 
Thr205 and neurotoxicity 168. However, it is still controversial how AICD becomes localized 
in the nucleus. Nakaya and Suzuki (2006) reported that AICD translocation into the nucleus 
is not dependent on AICD phosphorylation. Additionally, FE65-dependent gene 
transactivation mediated by AICD in the nucleus are regulated by APP phosphorylation 170. 
The anti-phospho-APP (Thr668) was also especially localized in spermatocytes during 
meiosis (arrows in Figures 27 and 28), suggesting that APP phosphorylation is specific 
during meiosis. In contrast, total-APP expression was not specific during meiosis, once 
during the meiotic division no major alterations in the expression pattern were observed. 
Additionally, it may be suggested that APP might be phosphorylated at AD-specific sites in 
meiosis. Thus, as future work, we should confirm if phosphorylated AICD is really in nuclei, 
and if so, attempt to identify the sub-nuclear structure where it is and its function there.  
In a similar way, phosphorylation of APP at Thr668 is also mitosis-specific 33,45,171. 
Suzuki and colleagues (1994) reported that APP is phosphorylated at Thr668 by CDK1/CDC2 
kinase in vitro, and in a cell cycle-dependent manner in vivo 33. At the G2/M phase of the 
cell cycle, when CDC2 kinase is most active, APP phosphorylation is maximal. Additionally, 
the levels of mature APP and immature APP do not change significantly. However, 
immature APP is altered qualitatively. Furthermore, the level of the secreted extracellular 
N-terminal domain (sAPP) is decreased, and that of the truncated intracellular C-terminal 
fragment (APPCOOH) is increased. Thus, and considering that APP isoforms are ubiquitously 
expressed in cells, cell cycle-regulated phosphorylation of these proteins may be important 
in modulating their normal physiological functions and/or their metabolism 33. Besides that, 
Judge et al. (2011) described that cell cycle activation not only induced the phosphorylation 
and proteolytic processing of APP (Aβ generation), but also affected the localization of 
phosphorylated APP in cells. Mitotic cells showed centrosome specific localization of 
phosphorylated APP 171. Additionally, another study proposed that the phosphorylation of 
structural or transient components of centrosomes may affect cell cycle dependent 
processes such as centrosome duplication and MT nucleation 172 (reviewed in Judge et al., 
2011 171). Thus, in addition to enhanced proteolytic cleavage, APP phosphorylation may 
influence cell proliferation through its association with the cell cycle machinery. The co-
localization of phosphorylated APP with MPM2, a metaphase protein marker, further 
reiterates APP's role as a growth-promoting molecule. Therefore, it is possible that high 
levels of phosphorylated APP may promote proliferation in dividing cells and centrosome 
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duplication or chromosome mis-segregation and cell death in post-mitotic neurons 171. 
APP's function as a mitogenic molecule is evident from the fact that its upregulation is 
associated with cancers of different organs 173,174 (reviewed in Judge et al., 2011 171), like 
testicular germ cell tumours 175. It has also been reported that APP and PS1 associate with 
other proteins at the centrosome and localize to centrosomes 176,177 (reviewed in Judge et 
al., 2011 171). 
Sandbrink et al. (1994) described relative amounts of differential expression of APP 
messenger ribonucleic acids (mRNAs) in peripheral tissue. In Wistar rats (7 or 8 months 
old), the main isoform expressed is APP770 (47%), followed by APP751 and L-APP752 (20% 
each), L-APP733 (7%), APP695 and L-APP696 (4% both), L-APP677 (2%), and APP714 (<1%). 
Thus, KPI domain encoding APP mRNA isoforms are the principal isoforms expressed in 
testis (94%) 178. These findings and the expected molecular weight of each isoform are 
summarized in Table 9.  
 
Table 9: Relative amounts of APP species in rat testis and their expected size. 
APP species 
Relative Quantity 
(mRNA) 178 
Expected size 179 
APP770 47% 
146 kDa (mature) 
129 kDa (sAPP) 
116 kDa (immature) 
APP751 20% 
139 kDa (mature) 
123 kDa (sAPP) 
112 kDa (immature) 
L-APP752 20%  
L-APP733 7%  
APP714 <1%  
APP695 and L-APP696 4% 
125 kDa (mature) 
109 kDa (sAPP) 
106 kDa (immature) 
L-APP677 2%  
Abbreviations: APP, Amyloid Precursor Protein; mRNA, messenger Ribonucleic Acid; 
sAPP, soluble Amyloid Precursor Protein. 
 
Through western blot analysis we detected two major bands with apparent molecular 
mass of 107 kDa and 104 kDa in mice testis, and one band at 110 kDa in rats testis (Figure 
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30). The major bands at 107 kDa (mouse) and 110 kDa (rat) probably represent full-length 
APP770, once that is the main isoform expressed in testis 178. The band at 104 kDa (mouse) 
may represents APLP2 124. The minor band at 74 kDa (rat) was also found in mouse brain 
180 and in previous work from our group with 22C11 and C-terminal antibodies, but has not 
yet been identified. Whereas the band at 54 kDa (mouse and rat) it may be an APLP2 
variant, and was described to be present in human sperm 124. The minor band at 42 kDa in 
mouse and at 43 kDa in rat probably represent an APP N-terminal cleavage product, and 
was recently described to be present in human embryonic stem cells 181. Although these 
APP cleavage products were reported to be in different types of cells, the functional 
significance of these products is still unknown 181.  
Similarly to Tau study, we attempted to evaluate the ageing influence in APP 
expression and its phosphorylation, through the western blot analysis. Spermatogenesis 
begins at around day 8 in mouse 182, and at approximately 5 days of age in rat 183. The sexual 
maturity is reached at 7 to 10 weeks in mouse 182, and at about 6 weeks in rat 183. When 
24-month-old, rats are mostly in a state of testicular regression 184. There is a tendency to 
decrease in APP expression between the ages of 2-month-old and 6-month-old (Figure 30 
and 31 – Mouse), using anti-APP 22C11. In rats, results of western blot analysis were 
inconsistent (Figure 30 and 31 – Rat), and was not possible to establish a logical conclusion. 
Statistical analysis could not be done, due to sample size (n < 3 in the majority of analysed 
ages). Thus, future work should increase the sample size and the age range in both mouse 
and rat to reach a most valid conclusion. 
Despite our best efforts, we obtained non-specific bindings in the western blot 
analysis using anti-APP CT695 and anti-phospho-APP (Thr668). After analysing all possible 
explanations, we concluded that polyclonal antibodies aren’t the best choice to use on 
tissue homogenization. Therefore, as future work, we should attempt other techniques to 
accomplish this aim, like immunoprecipitation. 
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7. Conclusion  
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In summary, this study comprised a detailed analysis of APP and Tau expression, as 
well as their phosphorylation patterns, during spermatogenesis (Table 10). Our results over 
Tau protein and its phosphorylation pattern are consistent with those previously published 
by H. Inoue et al. (2014) 73. PP1γ results are also in agreement with that Chakrabarti et al. 
(2007) described 159. However, PP1α results were not in conformity with what has been 
published.  
In this study, APP results are the major novel. There is a marked contrast in the 
distribution of total-APP and phosphorylated APP at Thr668. We demonstrate that site-
specific APP phosphorylation is specifically localized during spermatogenesis. Furthermore, 
APP phosphorylation may play a critical role in the meiosis process, probably related with 
its normal physiological functions and/or its metabolism. 
 
Table 10: Summary of relative expression of addressed proteins throughout spermatogenesis. 
 Spermatogonia Spermatocytes 
Spermatocytes in 
meiosis 
Round 
spermatids 
Elongated 
spermatids 
APP ++ ++ ++ ++ ++ 
Phospho-
APP 
(Thr668) 
+ ++ +++ + + 
Tau protein ++ + n.d. + ++ 
Phospho-
Tau (Ser202 
+ Thr205) 
++ ++ 
+++  
(P-TauS199, S202)73 
++ - 
PP1α +++ ++ n.d. ++ ++ 
PP1γ +++ ++ n.d. ++ +++ 
γ-Tubulin +++ ++ ++ ++ ++ 
Abbreviations: -, negative immunostaining; +, weak immunostaining; ++, moderate immunostaining; +++, 
strong immunostaining; n.d., not detected; APP, Amyloid Precursor Protein; PP, Serine/Threonine Protein 
Phosphatase; Ser, Serine; Thr, Threonine. 
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Future perspectives: 
• Study how ageing influences APP and Tau protein expression and their phosphorylation 
in testis through another technique than western blot analysis, like 
immunoprecipitation, as well as increasing the sample size and the age range; 
• Study other APP and Tau phosphorylatable residues in spermatogenesis, in order to 
unravel  their importance in meiosis; 
• Confirm whether phosphorylated AICD is present in spermatocyte nuclei, and identify 
the sub-nuclear structure where it is and its function there. 
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Immunohistochemistry Solutions 
 
Blocking Buffer (20 mL) 
0.1% v/v Triton X-100 ............................................................................. 20 µL 
4% v/v Foetal Bovine Serum (FBS) .......................................................... 800 µL 
5% w/v Bovine Serum Albumin (BSA)..................................................... 1 g 
Phosphate Buffered Saline (PBS) 1x ....................................................... make up to 20 mL 
Store at 4°C  
 
Citric Acid Solution, Sodium Citrate Solution, and Sodium Citrate Buffer 
a) 0.1 M Citric Acid Solution (1 L) 
Citric Acid Monohydrate (C6H8O7.H2O) .................................................. 21.01 g 
Deionized H2O ......................................................................................... make up to 1 L 
Store at 4°C 
 
b) 0.1 M Sodium Citrate Solution (1 L) 
Trisodium Citrate Dihydrate (Na3C6H5O7.2H2O) ..................................... 29.41 g 
Deionized H2O ......................................................................................... make up to 1 L 
Store at 4°C 
 
c) 0.01 M Sodium Citrate Buffer, pH 6.0 (500 mL) 
Citric Acid Solution (0.1 M stock solution) ............................................. 9 mL 
Sodium Citrate Solution (0.1 M stock solution) ..................................... 41 mL 
Deionized H2O ......................................................................................... make up to 500 mL 
Adjust pH to 6.0 ± 0.2 and store at 4°C 
 
Ethanol 90%, 80% and 70% 
 EtOH 90% EtOH 80% EtOH 70% 
Ethanol absolute ................... 450 mL .............................. 400 mL ............................. 350 mL 
Deionized H2O ....................... 50 mL ................................ 100 mL ............................. 150 mL 
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Phosphate Buffered Saline (PBS) 1x, pH 7.4 (500 mL) 
For a final volume of 500 mL, dissolve one pack of BupH™ Modified Dulbecco’s 
Phosphate Buffered Saline Pack (Thermo Scientific Pierce) in deionized H2O. Final 
composition: 0.002 M Potassium Phosphate; 0.008 M Sodium Phosphate; 0.01 M 
Potassium Chloride; 0.14 M Sodium Chloride. Store at 4°C. 
 
 
Western Blot Analysis Solutions 
 
Ammonium Persulphate (APS) 10% (10 mL) 
10% w/v APS ............................................................................................ 1 g 
Deionized H2O ......................................................................................... make up to 10 mL 
Store at 4°C by a maximum of one week 
 
Loading Buffer (LB) 4x (10 mL) 
Tris (1 M, pH 6.8 stock solution) ............................................................. 2.5 mL 
0.01% w/v Bromophenol Blue................................................................. 1 mg 
2% v/v β-mercaptoethanol ..................................................................... 2 mL 
8% w/v SDS .............................................................................................. 0.8 g 
40% v/v glycerol ...................................................................................... 4 mL 
Deionized H2O ......................................................................................... make up to 10 mL 
 
Lower Gel Buffer (LGB) 4x, pH 8.9 (500 mL) 
Tris base ................................................................................................... 90.825 g 
Sodium Dodecyl Sulphate (SDS) .............................................................. 2 g 
Deionized H2O ......................................................................................... make up to 500 mL 
Adjust pH to 8.9 ± 0.2 and store at 4°C 
 
Lysis Buffer (20 mL) 
Tris-HCl, pH 8.0 (50 mM, pH 8.0 stock solution) ..................................... 1 mL 
NaCl (120 mM stock solution) ................................................................. 2.4 mL 
4% w/v 3[(3-Cholamidopropyl)dimethylammonio]-propanesulfonic acid (CHAPS) 
 ................................................................................................................. 0.8 g 
Protease Inhibitors:  
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Leupeptin (5 mg/mL stock solution) ............................................. 4 µL 
Pepstatin A (1 mg/mL stock solution in DMSO) ............................ 132.2 µL 
Aprotinin (2.1 mg/mL stock solution) ........................................... 240 µL 
Phenylmethylsulfonyl Fluoride (PMSF) (100 mM stock solution) 977.8 µL 
Benzamidine (200 mM stock solution) ......................................... 1000 µL 
Sterile Deionized H2O ............................................................................. make up to 20 mL 
 
Resolving Gel (lower gel), 1 system – 5-20% gradient SDS polyacrylamide gel 
 5% 20% 
Sterile Deionized H2O ................................................. 17.4 mL ................................. 2.2 mL 
LGB .............................................................................. 7.5 mL ................................... 7.5 mL 
Acrylamide 30% .......................................................... 5 mL ...................................... 20 mL 
APS .............................................................................. 150 µL ................................... 150 µL 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) ..... 15 µL ..................................... 15 µL 
 
Running Buffer 10x, pH 8.3 (1 L) 
Tris base .................................................................................................. 30.3 g (250 mM) 
Glycine .................................................................................................... 150.14 g (2 M) 
1% w/v Sodium Dodecyl Sulphate (SDS) ................................................ 10 g  
Deionized H2O ......................................................................................... make up to 1 L 
Adjust pH to 8.3 ± 0.2 
 
Sodium Dodecyl Sulphate (SDS) 10% (10 mL) 
10% w/v SDS ........................................................................................... 1 g 
Deionized H2O ......................................................................................... make up to 10 mL 
 
Stacking gel (upper gel), 1 system – 3.5% SDS polyacrylamide gel 
Sterile Deionized H2O ............................................................................. 13.2 mL 
Upper Gel Buffer (UGB) .......................................................................... 4 mL 
Acrylamide 30% ...................................................................................... 2.4 mL 
SDS 10% .................................................................................................. 200 µL 
APS .......................................................................................................... 200 µL 
N,N,N′,N′-Tetramethylethylenediamine (TEMED) ................................. 20 µL 
 
 108 
Transfer Buffer 10x (2 L) 
Tris base ................................................................................................... 60.57 g 
Glycine ..................................................................................................... 280.0 g  
Deionized H2O ......................................................................................... make up to 2 L 
 
Transfer Buffer 1x, pH 8.3 (1 L) 
Transfer 10x ............................................................................................. 100 mL 
Methanol ................................................................................................. 200 mL  
Deionized H2O ......................................................................................... make up to 1 L 
Adjust pH to 8.3 ± 0.2 
 
1 M Tris, pH 6.8 (150 mL) 
Tris base ................................................................................................... 30.3 g 
Deionized H2O ......................................................................................... make up to 150 mL 
Adjust pH to 6.8 ± 0.2 
 
Upper Gel Buffer (UGB) 5x, pH 6.8 (500 mL) 
Tris base ................................................................................................... 37.845 g 
Deionized H2O ......................................................................................... make up to 500 mL 
Adjust pH to 6.8 ± 0.2 and store at 4°C 
 
 
Immunoblotting Solutions 
 
ECL detection reagent  
Solution A: 
3-aminophthalhydrazide (luminol) (20 mM stock solution in DMSO)  
 ....................................................................................................... 1.25 mL (0.1 mM) 
4-iodophenol (100 mM stock solution in DMSO) .......................... 5 mL (2 mM) 
Tris (0.1 M, pH 9.35 stock solution) ............................................... 125 mL (50 mM) 
Deionized H2O ................................................................................ make up to 250 mL 
Protect from light store at 4°C 
Solution B: hydrogen peroxide 
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Store at 4°C and just before use add 100 Solution A : 1 Solution B. 
 
Stripping Buffer, pH 6.7 (500 mL) 
Tris base .................................................................................................. 3.78 g (62.5 mM) 
2% w/v SDS ............................................................................................. 10 g 
Deionized H2O ......................................................................................... make up to 500 mL 
Adjust pH to 6.7 ± 0.2 
Just before use add 0.7% v/v β-mercaptoethanol ................................. 3.5 mL 
 
Tris Buffered Saline (TBS) 10x, pH 8.0 (1L) 
Tris base .................................................................................................. 12.11 g (100 mM) 
NaCl ......................................................................................................... 87.66 g (1.5 M) 
Deionized H2O ......................................................................................... make up to 1 L 
Adjust pH to 8.0 ± 0.2 and store at 4°C 
 
Tris Buffered Saline (TBS) 1x, pH 8.0 (1L) 
TBS 10x, pH 8.0 ....................................................................................... 100 mL 
Deionized H2O ......................................................................................... make up to 1 L 
Final composition: 10 mM Tris base; 150 mM Sodium Chloride. 
 
Tris Buffered Saline-Tween (TBS-T) 10x, pH 8.0 (1L) 
Tris base .................................................................................................. 12.11 g (100 mM) 
NaCl ......................................................................................................... 87.66 g (1.5 M) 
Deionized H2O ......................................................................................... make up to 1 L 
Adjust pH to 8.0 ± 0.2 and store at 4°C 
1% v/v Tween-20 .................................................................................... 10 mL 
 
Tris Buffered Saline-Tween (TBS-T) 1x, pH 8.0 (1L) 
TBS-T 10x, pH 8.0 .................................................................................... 100 mL 
Deionized H2O ......................................................................................... make up to 1 L 
Final composition: 10 mM Tris base; 150 mM Sodium Chloride; 0.1% v/v Tween-20. 
 
 
